<?xml version="1.0" encoding="US-ASCII" standalone="yes" ?>
<!-- RR Donnelley Xcelerate Instance Document, based on XBRL 2.1  http://www.rrdonnelley.com/ -->
<!-- Version:  6.21.3 -->
<!-- Round: 5 -->
<!-- Creation date: 2014-11-05T12:52:52Z -->
<!-- Copyright (c) 2005-2013 R.R. Donnelley &amp; Sons Company All Rights Reserved. -->
<xbrl xmlns="http://www.xbrl.org/2003/instance" xmlns:bind="http://www.bindtherapeutics.com/20140930" xmlns:country="http://xbrl.sec.gov/country/2013-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2014-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2014-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2014-01-31" xmlns:us-types="http://fasb.org/us-types/2014-01-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <xbrll:schemaRef xlink:arcrole="http://www.xbrl.org/2003/linkbase" xlink:href="bind-20140930.xsd" xlink:type="simple" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink"/>
  <dei:EntityCommonStockSharesOutstanding contextRef="eol_PE730401--1410-Q0009_STD_0_20141031_0" decimals="INF" id="id_4670348_F291F981-BC86-47D2-BE8C-679D8B7E44CF_2_5" unitRef="shares">16547549</dei:EntityCommonStockSharesOutstanding>
  <bind:AdditionalEarnOutContingentConsiderationPaymentMaximum contextRef="eol_PE730401--1410-Q0009_STD_0_20130331_0_1272072x1545620" decimals="-6" id="id_4670348_E4EDFA55-B8D6-45F2-ABD4-0C5B4B0E9BA2_2001_2" unitRef="iso4217_USD">110000000</bind:AdditionalEarnOutContingentConsiderationPaymentMaximum>
  <bind:PotentialToReceiveContingentPayments contextRef="eol_PE730401--1410-Q0009_STD_0_20130331_0_1272072x1545620" decimals="-5" id="id_4670348_E4EDFA55-B8D6-45F2-ABD4-0C5B4B0E9BA2_2001_1" unitRef="iso4217_USD">89500000</bind:PotentialToReceiveContingentPayments>
  <bind:PotentialToReceiveContingentPayments contextRef="eol_PE730401--1410-Q0009_STD_0_20130430_0_1272072x1367107" decimals="-6" id="id_4670348_B6684E62-1D77-47C3-96B1-CA830D930BF9_2001_1" unitRef="iso4217_USD">193000000</bind:PotentialToReceiveContingentPayments>
  <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="eol_PE730401--1410-Q0009_STD_0_20130630_0_1269523x1277596" decimals="-5" id="id_4670348_CE23F58B-9271-448F-A639-4E08DC56FDE9_3002_0" unitRef="iso4217_USD">8500000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
  <us-gaap:DebtAndCapitalLeaseObligations contextRef="eol_PE730401--1410-Q0009_STD_0_20130630_0_1269523x1277596" decimals="-5" id="id_4670348_CE23F58B-9271-448F-A639-4E08DC56FDE9_3002_1" unitRef="iso4217_USD">4500000</us-gaap:DebtAndCapitalLeaseObligations>
  <us-gaap:SharePrice contextRef="eol_PE730401--1410-Q0009_STD_0_20130925_0_1271382x1272538" decimals="INF" id="id_4670348_DA50667F-C395-423F-80EC-AA272DDC27BE_3001_1" unitRef="iso4217_USD_per_shares">15.00</us-gaap:SharePrice>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE730401--1410-Q0009_STD_0_20130930_0" decimals="-3" id="id_4670348_B3537E10-5158-4A83-93D5-A92106642A08_3002_33" unitRef="iso4217_USD">80715000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:SaleOfStockPricePerShare contextRef="eol_PE730401--1410-Q0009_STD_0_20131023_0" decimals="INF" id="id_4670348_DA50667F-C395-423F-80EC-AA272DDC27BE_2003_6" unitRef="iso4217_USD_per_shares">15.00</us-gaap:SaleOfStockPricePerShare>
  <us-gaap:CommonStockSharesIssued contextRef="eol_PE730401--1410-Q0009_STD_0_20140930_0" decimals="INF" id="id_4670348_800A97ED-BC38-44E0-AEF1-CDF4FD96BD9B_1_35" unitRef="shares">16547549</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesOutstanding contextRef="eol_PE730401--1410-Q0009_STD_0_20140930_0" decimals="INF" id="id_4670348_800A97ED-BC38-44E0-AEF1-CDF4FD96BD9B_1_36" unitRef="shares">16547549</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesAuthorized contextRef="eol_PE730401--1410-Q0009_STD_0_20140930_0" decimals="INF" id="id_4670348_800A97ED-BC38-44E0-AEF1-CDF4FD96BD9B_1_34" unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:PreferredStockSharesOutstanding contextRef="eol_PE730401--1410-Q0009_STD_0_20140930_0" decimals="INF" id="id_4670348_800A97ED-BC38-44E0-AEF1-CDF4FD96BD9B_1_31" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="eol_PE730401--1410-Q0009_STD_0_20140930_0" decimals="INF" id="id_4670348_800A97ED-BC38-44E0-AEF1-CDF4FD96BD9B_1_33" unitRef="iso4217_USD_per_shares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesAuthorized contextRef="eol_PE730401--1410-Q0009_STD_0_20140930_0" decimals="INF" id="id_4670348_800A97ED-BC38-44E0-AEF1-CDF4FD96BD9B_1_29" unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="eol_PE730401--1410-Q0009_STD_0_20140930_0" decimals="INF" id="id_4670348_800A97ED-BC38-44E0-AEF1-CDF4FD96BD9B_1_28" unitRef="iso4217_USD_per_shares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesIssued contextRef="eol_PE730401--1410-Q0009_STD_0_20140930_0" decimals="INF" id="id_4670348_800A97ED-BC38-44E0-AEF1-CDF4FD96BD9B_1_30" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:DeferredRevenueNoncurrent contextRef="eol_PE730401--1410-Q0009_STD_0_20140930_0" decimals="-3" id="id_4670348_800A97ED-BC38-44E0-AEF1-CDF4FD96BD9B_1_21" unitRef="iso4217_USD">440000</us-gaap:DeferredRevenueNoncurrent>
  <us-gaap:DeferredRentCreditCurrent contextRef="eol_PE730401--1410-Q0009_STD_0_20140930_0" decimals="-3" id="id_4670348_800A97ED-BC38-44E0-AEF1-CDF4FD96BD9B_1_17" unitRef="iso4217_USD">505000</us-gaap:DeferredRentCreditCurrent>
  <us-gaap:PreferredStockValue contextRef="eol_PE730401--1410-Q0009_STD_0_20140930_0" decimals="-3" id="id_4670348_800A97ED-BC38-44E0-AEF1-CDF4FD96BD9B_1_27" unitRef="iso4217_USD">0</us-gaap:PreferredStockValue>
  <us-gaap:LiabilitiesCurrent contextRef="eol_PE730401--1410-Q0009_STD_0_20140930_0" decimals="-3" id="id_4670348_800A97ED-BC38-44E0-AEF1-CDF4FD96BD9B_1_18" unitRef="iso4217_USD">12290000</us-gaap:LiabilitiesCurrent>
  <us-gaap:LiabilitiesNoncurrent contextRef="eol_PE730401--1410-Q0009_STD_0_20140930_0" decimals="-3" id="id_4670348_800A97ED-BC38-44E0-AEF1-CDF4FD96BD9B_1_23" unitRef="iso4217_USD">3535000</us-gaap:LiabilitiesNoncurrent>
  <us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount contextRef="eol_PE730401--1410-Q0009_STD_0_20140930_0" decimals="INF" id="id_4670348_6BE59230-395C-4DB0-9E73-7ACAC2BC781E_1_0" unitRef="iso4217_USD">0</us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount>
  <us-gaap:CommonStockValue contextRef="eol_PE730401--1410-Q0009_STD_0_20140930_0" decimals="-3" id="id_4670348_800A97ED-BC38-44E0-AEF1-CDF4FD96BD9B_1_32" unitRef="iso4217_USD">2000</us-gaap:CommonStockValue>
  <us-gaap:CommitmentsAndContingencies contextRef="eol_PE730401--1410-Q0009_STD_0_20140930_0" id="id_4670348_800A97ED-BC38-44E0-AEF1-CDF4FD96BD9B_1_25" unitRef="iso4217_USD" xsi:nil="true"/>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="eol_PE730401--1410-Q0009_STD_0_20140930_0" decimals="-3" id="id_4670348_800A97ED-BC38-44E0-AEF1-CDF4FD96BD9B_1_39" unitRef="iso4217_USD">-1451000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:AccountsPayableCurrent contextRef="eol_PE730401--1410-Q0009_STD_0_20140930_0" decimals="-3" id="id_4670348_800A97ED-BC38-44E0-AEF1-CDF4FD96BD9B_1_14" unitRef="iso4217_USD">662000</us-gaap:AccountsPayableCurrent>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="eol_PE730401--1410-Q0009_STD_0_20140930_0" decimals="-3" id="id_4670348_800A97ED-BC38-44E0-AEF1-CDF4FD96BD9B_1_38" unitRef="iso4217_USD">-128785000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:LongTermDebtCurrent contextRef="eol_PE730401--1410-Q0009_STD_0_20140930_0" decimals="-3" id="id_4670348_800A97ED-BC38-44E0-AEF1-CDF4FD96BD9B_1_13" unitRef="iso4217_USD">1746000</us-gaap:LongTermDebtCurrent>
  <us-gaap:AccruedLiabilitiesCurrent contextRef="eol_PE730401--1410-Q0009_STD_0_20140930_0" decimals="-3" id="id_4670348_800A97ED-BC38-44E0-AEF1-CDF4FD96BD9B_1_15" unitRef="iso4217_USD">4176000</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:StockholdersEquity contextRef="eol_PE730401--1410-Q0009_STD_0_20140930_0" decimals="-3" id="id_4670348_800A97ED-BC38-44E0-AEF1-CDF4FD96BD9B_1_40" unitRef="iso4217_USD">46512000</us-gaap:StockholdersEquity>
  <us-gaap:OtherLiabilitiesNoncurrent contextRef="eol_PE730401--1410-Q0009_STD_0_20140930_0" decimals="-3" id="id_4670348_800A97ED-BC38-44E0-AEF1-CDF4FD96BD9B_1_22" unitRef="iso4217_USD">1147000</us-gaap:OtherLiabilitiesNoncurrent>
  <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="eol_PE730401--1410-Q0009_STD_0_20140930_0" decimals="-3" id="id_4670348_15309E0A-D8EA-4452-99F2-6757219789DE_1_2" unitRef="iso4217_USD">1782000</us-gaap:OtherAccruedLiabilitiesCurrent>
  <us-gaap:LongTermDebtNoncurrent contextRef="eol_PE730401--1410-Q0009_STD_0_20140930_0" decimals="-3" id="id_4670348_800A97ED-BC38-44E0-AEF1-CDF4FD96BD9B_1_20" unitRef="iso4217_USD">1948000</us-gaap:LongTermDebtNoncurrent>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="eol_PE730401--1410-Q0009_STD_0_20140930_0" decimals="-3" id="id_4670348_800A97ED-BC38-44E0-AEF1-CDF4FD96BD9B_1_41" unitRef="iso4217_USD">62337000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:AdditionalPaidInCapital contextRef="eol_PE730401--1410-Q0009_STD_0_20140930_0" decimals="-3" id="id_4670348_800A97ED-BC38-44E0-AEF1-CDF4FD96BD9B_1_37" unitRef="iso4217_USD">176746000</us-gaap:AdditionalPaidInCapital>
  <us-gaap:DeferredRevenueCurrent contextRef="eol_PE730401--1410-Q0009_STD_0_20140930_0" decimals="-3" id="id_4670348_800A97ED-BC38-44E0-AEF1-CDF4FD96BD9B_1_16" unitRef="iso4217_USD">5201000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:LineOfCredit contextRef="eol_PE730401--1410-Q0009_STD_0_20140930_0" decimals="-5" id="id_4670348_F42EDA83-2E23-4302-82F9-A31E62F850C3_2_4" unitRef="iso4217_USD">3700000</us-gaap:LineOfCredit>
  <us-gaap:Liabilities contextRef="eol_PE730401--1410-Q0009_STD_0_20140930_0" decimals="-3" id="id_4670348_800A97ED-BC38-44E0-AEF1-CDF4FD96BD9B_1_24" unitRef="iso4217_USD">15825000</us-gaap:Liabilities>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="eol_PE730401--1410-Q0009_STD_0_20140930_0" decimals="-3" id="id_4670348_15309E0A-D8EA-4452-99F2-6757219789DE_1_0" unitRef="iso4217_USD">1365000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="eol_PE730401--1410-Q0009_STD_0_20140930_0" decimals="-3" id="id_4670348_9921B936-6F4D-45D3-958B-B72AA71276A6_3_2" unitRef="iso4217_USD">4000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE730401--1410-Q0009_STD_0_20140930_0" decimals="-3" id="id_4670348_800A97ED-BC38-44E0-AEF1-CDF4FD96BD9B_1_1" unitRef="iso4217_USD">23760000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="eol_PE730401--1410-Q0009_STD_0_20140930_0" decimals="-5" id="id_4670348_112C7D26-7FF2-48B7-BF3E-7F5D08A14E18_2_0" unitRef="iso4217_USD">6100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
  <us-gaap:MoneyMarketFundsAtCarryingValue contextRef="eol_PE730401--1410-Q0009_STD_0_20140930_0" decimals="-5" id="id_4670348_5E22E80A-182B-41CD-B29A-1CDF6E7FADFB_1_0" unitRef="iso4217_USD">19100000</us-gaap:MoneyMarketFundsAtCarryingValue>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="eol_PE730401--1410-Q0009_STD_0_20140930_0" decimals="-3" id="id_4670348_800A97ED-BC38-44E0-AEF1-CDF4FD96BD9B_1_6" unitRef="iso4217_USD">6272000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:AvailableForSaleSecurities contextRef="eol_PE730401--1410-Q0009_STD_0_20140930_0" decimals="-3" id="id_4670348_9921B936-6F4D-45D3-958B-B72AA71276A6_3_4" unitRef="iso4217_USD">27152000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="eol_PE730401--1410-Q0009_STD_0_20140930_0" decimals="-3" id="id_4670348_800A97ED-BC38-44E0-AEF1-CDF4FD96BD9B_1_4" unitRef="iso4217_USD">780000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent contextRef="eol_PE730401--1410-Q0009_STD_0_20140930_0" decimals="-3" id="id_4670348_800A97ED-BC38-44E0-AEF1-CDF4FD96BD9B_1_8" unitRef="iso4217_USD">1911000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
  <us-gaap:CertificatesOfDepositAtCarryingValue contextRef="eol_PE730401--1410-Q0009_STD_0_20140930_0" decimals="-5" id="id_4670348_5E22E80A-182B-41CD-B29A-1CDF6E7FADFB_1_1" unitRef="iso4217_USD">500000</us-gaap:CertificatesOfDepositAtCarryingValue>
  <us-gaap:Assets contextRef="eol_PE730401--1410-Q0009_STD_0_20140930_0" decimals="-3" id="id_4670348_800A97ED-BC38-44E0-AEF1-CDF4FD96BD9B_1_10" unitRef="iso4217_USD">62337000</us-gaap:Assets>
  <us-gaap:ShortTermInvestments contextRef="eol_PE730401--1410-Q0009_STD_0_20140930_0" decimals="-3" id="id_4670348_800A97ED-BC38-44E0-AEF1-CDF4FD96BD9B_1_2" unitRef="iso4217_USD">27152000</us-gaap:ShortTermInvestments>
  <us-gaap:AccountsReceivableNetCurrent contextRef="eol_PE730401--1410-Q0009_STD_0_20140930_0" decimals="-3" id="id_4670348_800A97ED-BC38-44E0-AEF1-CDF4FD96BD9B_1_3" unitRef="iso4217_USD">2441000</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="eol_PE730401--1410-Q0009_STD_0_20140930_0" decimals="-3" id="id_4670348_9921B936-6F4D-45D3-958B-B72AA71276A6_3_1" unitRef="iso4217_USD">27155000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
  <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="eol_PE730401--1410-Q0009_STD_0_20140930_0" decimals="-3" id="id_4670348_9921B936-6F4D-45D3-958B-B72AA71276A6_3_3" unitRef="iso4217_USD">7000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
  <us-gaap:FairValueLiabilitiesLevel1ToLevel2TransfersAmount contextRef="eol_PE730401--1410-Q0009_STD_0_20140930_0" decimals="INF" id="id_4670348_6BE59230-395C-4DB0-9E73-7ACAC2BC781E_1_1" unitRef="iso4217_USD">0</us-gaap:FairValueLiabilitiesLevel1ToLevel2TransfersAmount>
  <us-gaap:OtherAssetsNoncurrent contextRef="eol_PE730401--1410-Q0009_STD_0_20140930_0" decimals="-3" id="id_4670348_800A97ED-BC38-44E0-AEF1-CDF4FD96BD9B_1_9" unitRef="iso4217_USD">21000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:AssetsCurrent contextRef="eol_PE730401--1410-Q0009_STD_0_20140930_0" decimals="-3" id="id_4670348_800A97ED-BC38-44E0-AEF1-CDF4FD96BD9B_1_5" unitRef="iso4217_USD">54133000</us-gaap:AssetsCurrent>
  <bind:AccruedClinicalTrialCostsCurrent contextRef="eol_PE730401--1410-Q0009_STD_0_20140930_0" decimals="-3" id="id_4670348_15309E0A-D8EA-4452-99F2-6757219789DE_1_1" unitRef="iso4217_USD">1029000</bind:AccruedClinicalTrialCostsCurrent>
  <bind:FairValueOfShortTermInvestmentsReclassifiedToLevelThreeInputs contextRef="eol_PE730401--1410-Q0009_STD_0_20140930_0" decimals="INF" id="id_4670348_6BE59230-395C-4DB0-9E73-7ACAC2BC781E_1_2" unitRef="iso4217_USD">0</bind:FairValueOfShortTermInvestmentsReclassifiedToLevelThreeInputs>
  <bind:FairValueOfLongTermInvestmentsReclassifiedToLevelThreeInputs contextRef="eol_PE730401--1410-Q0009_STD_0_20140930_0" decimals="INF" id="id_4670348_6BE59230-395C-4DB0-9E73-7ACAC2BC781E_1_3" unitRef="iso4217_USD">0</bind:FairValueOfLongTermInvestmentsReclassifiedToLevelThreeInputs>
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE730401--1410-Q0009_STD_0_20140930_0_1269038x1269048" decimals="-3" id="id_4670348_166BB6AA-3B56-4FA8-8087-B1DC27625C8D_5003_4" unitRef="iso4217_USD">27152000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AvailableForSaleSecurities contextRef="eol_PE730401--1410-Q0009_STD_0_20140930_0_1269038x1269048_1275669x1270387" decimals="-3" id="id_4670348_166BB6AA-3B56-4FA8-8087-B1DC27625C8D_7003_2" unitRef="iso4217_USD">9893000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:AvailableForSaleSecurities contextRef="eol_PE730401--1410-Q0009_STD_0_20140930_0_1269038x1269048_1276335x1276695" decimals="-3" id="id_4670348_166BB6AA-3B56-4FA8-8087-B1DC27625C8D_9003_3" unitRef="iso4217_USD">17259000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE730401--1410-Q0009_STD_0_20140930_0_1269038x1272304" decimals="-3" id="id_4670348_166BB6AA-3B56-4FA8-8087-B1DC27625C8D_5002_4" unitRef="iso4217_USD">19625000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE730401--1410-Q0009_STD_0_20140930_0_1269038x1272304_1275669x1277587" decimals="-3" id="id_4670348_166BB6AA-3B56-4FA8-8087-B1DC27625C8D_8002_1" unitRef="iso4217_USD">19625000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:FDICIndemnificationAsset contextRef="eol_PE730401--1410-Q0009_STD_0_20140930_0_1269523x1275948_1280806x1270387" decimals="INF" id="id_4670348_DAE93F34-720D-43E9-9828-5829AE57083D_1001_3" unitRef="iso4217_USD">250000</us-gaap:FDICIndemnificationAsset>
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE730401--1410-Q0009_STD_0_20140930_0_1272289x1278641" decimals="-3" id="id_4670348_166BB6AA-3B56-4FA8-8087-B1DC27625C8D_5001_4" unitRef="iso4217_USD">46777000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AvailableForSaleSecurities contextRef="eol_PE730401--1410-Q0009_STD_0_20140930_0_1272289x1278641_1275669x1270387" decimals="-3" id="id_4670348_166BB6AA-3B56-4FA8-8087-B1DC27625C8D_7001_2" unitRef="iso4217_USD">9893000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE730401--1410-Q0009_STD_0_20140930_0_1272289x1278641_1275669x1277587" decimals="-3" id="id_4670348_166BB6AA-3B56-4FA8-8087-B1DC27625C8D_8001_1" unitRef="iso4217_USD">19625000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AvailableForSaleSecurities contextRef="eol_PE730401--1410-Q0009_STD_0_20140930_0_1272289x1278641_1276335x1276695" decimals="-3" id="id_4670348_166BB6AA-3B56-4FA8-8087-B1DC27625C8D_9001_3" unitRef="iso4217_USD">17259000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="eol_PE730401--1410-Q0009_STD_0_20140930_0_1280806x1270387" id="id_4670348_9921B936-6F4D-45D3-958B-B72AA71276A6_1_2" unitRef="iso4217_USD" xsi:nil="true"/>
  <us-gaap:AvailableForSaleSecurities contextRef="eol_PE730401--1410-Q0009_STD_0_20140930_0_1280806x1270387" decimals="-3" id="id_4670348_9921B936-6F4D-45D3-958B-B72AA71276A6_1_4" unitRef="iso4217_USD">9893000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="eol_PE730401--1410-Q0009_STD_0_20140930_0_1280806x1270387" decimals="-3" id="id_4670348_9921B936-6F4D-45D3-958B-B72AA71276A6_1_1" unitRef="iso4217_USD">9900000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
  <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="eol_PE730401--1410-Q0009_STD_0_20140930_0_1280806x1270387" decimals="-3" id="id_4670348_9921B936-6F4D-45D3-958B-B72AA71276A6_1_3" unitRef="iso4217_USD">7000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
  <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="eol_PE730401--1410-Q0009_STD_0_20140930_0_1280806x1276695" decimals="-3" id="id_4670348_9921B936-6F4D-45D3-958B-B72AA71276A6_2_2" unitRef="iso4217_USD">4000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
  <us-gaap:AvailableForSaleSecurities contextRef="eol_PE730401--1410-Q0009_STD_0_20140930_0_1280806x1276695" decimals="-3" id="id_4670348_9921B936-6F4D-45D3-958B-B72AA71276A6_2_4" unitRef="iso4217_USD">17259000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="eol_PE730401--1410-Q0009_STD_0_20140930_0_1280806x1276695" decimals="-3" id="id_4670348_9921B936-6F4D-45D3-958B-B72AA71276A6_2_1" unitRef="iso4217_USD">17255000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="eol_PE730401--1410-Q0009_STD_0_20140930_0_1280964x1326831" decimals="INF" id="id_4670348_6B71623E-F724-4F57-96CB-8B93E7BF8572_1002_1" unitRef="shares">1562671</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE730401--1410-Q0009_STD_0_20121231_0" decimals="-3" id="id_4670348_B3537E10-5158-4A83-93D5-A92106642A08_4001_32" unitRef="iso4217_USD">4886000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CommonStockSharesIssued contextRef="eol_PE730401--1410-Q0009_STD_0_20131231_0" decimals="INF" id="id_4670348_800A97ED-BC38-44E0-AEF1-CDF4FD96BD9B_2_35" unitRef="shares">16438706</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesOutstanding contextRef="eol_PE730401--1410-Q0009_STD_0_20131231_0" decimals="INF" id="id_4670348_800A97ED-BC38-44E0-AEF1-CDF4FD96BD9B_2_36" unitRef="shares">16410840</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesAuthorized contextRef="eol_PE730401--1410-Q0009_STD_0_20131231_0" decimals="INF" id="id_4670348_800A97ED-BC38-44E0-AEF1-CDF4FD96BD9B_2_34" unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:PreferredStockSharesOutstanding contextRef="eol_PE730401--1410-Q0009_STD_0_20131231_0" decimals="INF" id="id_4670348_800A97ED-BC38-44E0-AEF1-CDF4FD96BD9B_2_31" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="eol_PE730401--1410-Q0009_STD_0_20131231_0" decimals="INF" id="id_4670348_800A97ED-BC38-44E0-AEF1-CDF4FD96BD9B_2_33" unitRef="iso4217_USD_per_shares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesAuthorized contextRef="eol_PE730401--1410-Q0009_STD_0_20131231_0" decimals="INF" id="id_4670348_800A97ED-BC38-44E0-AEF1-CDF4FD96BD9B_2_29" unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="eol_PE730401--1410-Q0009_STD_0_20131231_0" decimals="INF" id="id_4670348_800A97ED-BC38-44E0-AEF1-CDF4FD96BD9B_2_28" unitRef="iso4217_USD_per_shares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesIssued contextRef="eol_PE730401--1410-Q0009_STD_0_20131231_0" decimals="INF" id="id_4670348_800A97ED-BC38-44E0-AEF1-CDF4FD96BD9B_2_30" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:DeferredRevenueNoncurrent contextRef="eol_PE730401--1410-Q0009_STD_0_20131231_0" decimals="-3" id="id_4670348_800A97ED-BC38-44E0-AEF1-CDF4FD96BD9B_2_21" unitRef="iso4217_USD">2384000</us-gaap:DeferredRevenueNoncurrent>
  <us-gaap:DeferredRentCreditCurrent contextRef="eol_PE730401--1410-Q0009_STD_0_20131231_0" decimals="-3" id="id_4670348_800A97ED-BC38-44E0-AEF1-CDF4FD96BD9B_2_17" unitRef="iso4217_USD">513000</us-gaap:DeferredRentCreditCurrent>
  <us-gaap:PreferredStockValue contextRef="eol_PE730401--1410-Q0009_STD_0_20131231_0" decimals="-3" id="id_4670348_800A97ED-BC38-44E0-AEF1-CDF4FD96BD9B_2_27" unitRef="iso4217_USD">0</us-gaap:PreferredStockValue>
  <us-gaap:LiabilitiesCurrent contextRef="eol_PE730401--1410-Q0009_STD_0_20131231_0" decimals="-3" id="id_4670348_800A97ED-BC38-44E0-AEF1-CDF4FD96BD9B_2_18" unitRef="iso4217_USD">12061000</us-gaap:LiabilitiesCurrent>
  <us-gaap:LiabilitiesNoncurrent contextRef="eol_PE730401--1410-Q0009_STD_0_20131231_0" decimals="-3" id="id_4670348_800A97ED-BC38-44E0-AEF1-CDF4FD96BD9B_2_23" unitRef="iso4217_USD">7033000</us-gaap:LiabilitiesNoncurrent>
  <us-gaap:CommonStockValue contextRef="eol_PE730401--1410-Q0009_STD_0_20131231_0" decimals="-3" id="id_4670348_800A97ED-BC38-44E0-AEF1-CDF4FD96BD9B_2_32" unitRef="iso4217_USD">2000</us-gaap:CommonStockValue>
  <us-gaap:CommitmentsAndContingencies contextRef="eol_PE730401--1410-Q0009_STD_0_20131231_0" id="id_4670348_800A97ED-BC38-44E0-AEF1-CDF4FD96BD9B_2_25" unitRef="iso4217_USD" xsi:nil="true"/>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="eol_PE730401--1410-Q0009_STD_0_20131231_0" decimals="-3" id="id_4670348_800A97ED-BC38-44E0-AEF1-CDF4FD96BD9B_2_39" unitRef="iso4217_USD">-414000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:AccountsPayableCurrent contextRef="eol_PE730401--1410-Q0009_STD_0_20131231_0" decimals="-3" id="id_4670348_800A97ED-BC38-44E0-AEF1-CDF4FD96BD9B_2_14" unitRef="iso4217_USD">2643000</us-gaap:AccountsPayableCurrent>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="eol_PE730401--1410-Q0009_STD_0_20131231_0" decimals="-3" id="id_4670348_800A97ED-BC38-44E0-AEF1-CDF4FD96BD9B_2_38" unitRef="iso4217_USD">-104742000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:LongTermDebtCurrent contextRef="eol_PE730401--1410-Q0009_STD_0_20131231_0" decimals="-3" id="id_4670348_800A97ED-BC38-44E0-AEF1-CDF4FD96BD9B_2_13" unitRef="iso4217_USD">1411000</us-gaap:LongTermDebtCurrent>
  <us-gaap:AccruedLiabilitiesCurrent contextRef="eol_PE730401--1410-Q0009_STD_0_20131231_0" decimals="-3" id="id_4670348_800A97ED-BC38-44E0-AEF1-CDF4FD96BD9B_2_15" unitRef="iso4217_USD">2408000</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:StockholdersEquity contextRef="eol_PE730401--1410-Q0009_STD_0_20131231_0" decimals="-3" id="id_4670348_800A97ED-BC38-44E0-AEF1-CDF4FD96BD9B_2_40" unitRef="iso4217_USD">69314000</us-gaap:StockholdersEquity>
  <us-gaap:OtherLiabilitiesNoncurrent contextRef="eol_PE730401--1410-Q0009_STD_0_20131231_0" decimals="-3" id="id_4670348_800A97ED-BC38-44E0-AEF1-CDF4FD96BD9B_2_22" unitRef="iso4217_USD">1375000</us-gaap:OtherLiabilitiesNoncurrent>
  <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="eol_PE730401--1410-Q0009_STD_0_20131231_0" decimals="-3" id="id_4670348_15309E0A-D8EA-4452-99F2-6757219789DE_2_2" unitRef="iso4217_USD">1087000</us-gaap:OtherAccruedLiabilitiesCurrent>
  <us-gaap:LongTermDebtNoncurrent contextRef="eol_PE730401--1410-Q0009_STD_0_20131231_0" decimals="-3" id="id_4670348_800A97ED-BC38-44E0-AEF1-CDF4FD96BD9B_2_20" unitRef="iso4217_USD">3274000</us-gaap:LongTermDebtNoncurrent>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="eol_PE730401--1410-Q0009_STD_0_20131231_0" decimals="-3" id="id_4670348_800A97ED-BC38-44E0-AEF1-CDF4FD96BD9B_2_41" unitRef="iso4217_USD">88408000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:AdditionalPaidInCapital contextRef="eol_PE730401--1410-Q0009_STD_0_20131231_0" decimals="-3" id="id_4670348_800A97ED-BC38-44E0-AEF1-CDF4FD96BD9B_2_37" unitRef="iso4217_USD">174468000</us-gaap:AdditionalPaidInCapital>
  <us-gaap:DeferredRevenueCurrent contextRef="eol_PE730401--1410-Q0009_STD_0_20131231_0" decimals="-3" id="id_4670348_800A97ED-BC38-44E0-AEF1-CDF4FD96BD9B_2_16" unitRef="iso4217_USD">5086000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:LineOfCredit contextRef="eol_PE730401--1410-Q0009_STD_0_20131231_0" decimals="-5" id="id_4670348_F42EDA83-2E23-4302-82F9-A31E62F850C3_3_4" unitRef="iso4217_USD">4500000</us-gaap:LineOfCredit>
  <us-gaap:Liabilities contextRef="eol_PE730401--1410-Q0009_STD_0_20131231_0" decimals="-3" id="id_4670348_800A97ED-BC38-44E0-AEF1-CDF4FD96BD9B_2_24" unitRef="iso4217_USD">19094000</us-gaap:Liabilities>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="eol_PE730401--1410-Q0009_STD_0_20131231_0" decimals="-3" id="id_4670348_15309E0A-D8EA-4452-99F2-6757219789DE_2_0" unitRef="iso4217_USD">612000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="eol_PE730401--1410-Q0009_STD_0_20131231_0" decimals="-3" id="id_4670348_9921B936-6F4D-45D3-958B-B72AA71276A6_6_2" unitRef="iso4217_USD">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE730401--1410-Q0009_STD_0_20131231_0" decimals="-3" id="id_4670348_800A97ED-BC38-44E0-AEF1-CDF4FD96BD9B_2_1" unitRef="iso4217_USD">51612000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:MoneyMarketFundsAtCarryingValue contextRef="eol_PE730401--1410-Q0009_STD_0_20131231_0" decimals="-5" id="id_4670348_5E22E80A-182B-41CD-B29A-1CDF6E7FADFB_2_0" unitRef="iso4217_USD">44700000</us-gaap:MoneyMarketFundsAtCarryingValue>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="eol_PE730401--1410-Q0009_STD_0_20131231_0" decimals="-3" id="id_4670348_800A97ED-BC38-44E0-AEF1-CDF4FD96BD9B_2_6" unitRef="iso4217_USD">6079000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:AvailableForSaleSecurities contextRef="eol_PE730401--1410-Q0009_STD_0_20131231_0" decimals="-3" id="id_4670348_9921B936-6F4D-45D3-958B-B72AA71276A6_6_4" unitRef="iso4217_USD">25771000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="eol_PE730401--1410-Q0009_STD_0_20131231_0" decimals="-3" id="id_4670348_800A97ED-BC38-44E0-AEF1-CDF4FD96BD9B_2_4" unitRef="iso4217_USD">1532000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent contextRef="eol_PE730401--1410-Q0009_STD_0_20131231_0" decimals="-3" id="id_4670348_800A97ED-BC38-44E0-AEF1-CDF4FD96BD9B_2_8" unitRef="iso4217_USD">2084000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
  <us-gaap:CertificatesOfDepositAtCarryingValue contextRef="eol_PE730401--1410-Q0009_STD_0_20131231_0" decimals="-5" id="id_4670348_5E22E80A-182B-41CD-B29A-1CDF6E7FADFB_2_1" unitRef="iso4217_USD">500000</us-gaap:CertificatesOfDepositAtCarryingValue>
  <us-gaap:LongTermInvestments contextRef="eol_PE730401--1410-Q0009_STD_0_20131231_0" decimals="-3" id="id_4670348_800A97ED-BC38-44E0-AEF1-CDF4FD96BD9B_2_7" unitRef="iso4217_USD">15387000</us-gaap:LongTermInvestments>
  <us-gaap:Assets contextRef="eol_PE730401--1410-Q0009_STD_0_20131231_0" decimals="-3" id="id_4670348_800A97ED-BC38-44E0-AEF1-CDF4FD96BD9B_2_10" unitRef="iso4217_USD">88408000</us-gaap:Assets>
  <us-gaap:ShortTermInvestments contextRef="eol_PE730401--1410-Q0009_STD_0_20131231_0" decimals="-3" id="id_4670348_800A97ED-BC38-44E0-AEF1-CDF4FD96BD9B_2_2" unitRef="iso4217_USD">10384000</us-gaap:ShortTermInvestments>
  <us-gaap:AccountsReceivableNetCurrent contextRef="eol_PE730401--1410-Q0009_STD_0_20131231_0" decimals="-3" id="id_4670348_800A97ED-BC38-44E0-AEF1-CDF4FD96BD9B_2_3" unitRef="iso4217_USD">1269000</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="eol_PE730401--1410-Q0009_STD_0_20131231_0" decimals="-3" id="id_4670348_9921B936-6F4D-45D3-958B-B72AA71276A6_6_1" unitRef="iso4217_USD">25771000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
  <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="eol_PE730401--1410-Q0009_STD_0_20131231_0" decimals="-3" id="id_4670348_9921B936-6F4D-45D3-958B-B72AA71276A6_6_3" unitRef="iso4217_USD">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
  <us-gaap:OtherAssetsNoncurrent contextRef="eol_PE730401--1410-Q0009_STD_0_20131231_0" decimals="-3" id="id_4670348_800A97ED-BC38-44E0-AEF1-CDF4FD96BD9B_2_9" unitRef="iso4217_USD">61000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:AssetsCurrent contextRef="eol_PE730401--1410-Q0009_STD_0_20131231_0" decimals="-3" id="id_4670348_800A97ED-BC38-44E0-AEF1-CDF4FD96BD9B_2_5" unitRef="iso4217_USD">64797000</us-gaap:AssetsCurrent>
  <bind:AccruedClinicalTrialCostsCurrent contextRef="eol_PE730401--1410-Q0009_STD_0_20131231_0" decimals="-3" id="id_4670348_15309E0A-D8EA-4452-99F2-6757219789DE_2_1" unitRef="iso4217_USD">709000</bind:AccruedClinicalTrialCostsCurrent>
  <bind:LineOfCreditFacilityExpiredRemainingBorrowingCapacity contextRef="eol_PE730401--1410-Q0009_STD_0_20131231_0" decimals="-5" id="id_4670348_CE23F58B-9271-448F-A639-4E08DC56FDE9_3_4" unitRef="iso4217_USD">4000000</bind:LineOfCreditFacilityExpiredRemainingBorrowingCapacity>
  <bind:FairValueOfShortTermInvestmentsReclassifiedToLevelThreeInputs contextRef="eol_PE730401--1410-Q0009_STD_0_20131231_0" decimals="INF" id="id_4670348_6BE59230-395C-4DB0-9E73-7ACAC2BC781E_2_2" unitRef="iso4217_USD">0</bind:FairValueOfShortTermInvestmentsReclassifiedToLevelThreeInputs>
  <bind:FairValueOfLongTermInvestmentsReclassifiedToLevelThreeInputs contextRef="eol_PE730401--1410-Q0009_STD_0_20131231_0" decimals="INF" id="id_4670348_6BE59230-395C-4DB0-9E73-7ACAC2BC781E_2_3" unitRef="iso4217_USD">0</bind:FairValueOfLongTermInvestmentsReclassifiedToLevelThreeInputs>
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE730401--1410-Q0009_STD_0_20131231_0_1269038x1269048" decimals="-3" id="id_4670348_166BB6AA-3B56-4FA8-8087-B1DC27625C8D_1003_8" unitRef="iso4217_USD">25771000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AvailableForSaleSecurities contextRef="eol_PE730401--1410-Q0009_STD_0_20131231_0_1269038x1269048_1275669x1270387" decimals="-3" id="id_4670348_166BB6AA-3B56-4FA8-8087-B1DC27625C8D_2003_6" unitRef="iso4217_USD">1783000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:AvailableForSaleSecurities contextRef="eol_PE730401--1410-Q0009_STD_0_20131231_0_1269038x1269048_1276335x1276695" decimals="-3" id="id_4670348_166BB6AA-3B56-4FA8-8087-B1DC27625C8D_4003_7" unitRef="iso4217_USD">23988000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE730401--1410-Q0009_STD_0_20131231_0_1269038x1272304" decimals="-3" id="id_4670348_166BB6AA-3B56-4FA8-8087-B1DC27625C8D_1002_8" unitRef="iso4217_USD">45268000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE730401--1410-Q0009_STD_0_20131231_0_1269038x1272304_1275669x1277587" decimals="-3" id="id_4670348_166BB6AA-3B56-4FA8-8087-B1DC27625C8D_3002_5" unitRef="iso4217_USD">45268000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE730401--1410-Q0009_STD_0_20131231_0_1272289x1278641" decimals="-3" id="id_4670348_166BB6AA-3B56-4FA8-8087-B1DC27625C8D_1001_8" unitRef="iso4217_USD">71039000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AvailableForSaleSecurities contextRef="eol_PE730401--1410-Q0009_STD_0_20131231_0_1272289x1278641_1275669x1270387" decimals="-3" id="id_4670348_166BB6AA-3B56-4FA8-8087-B1DC27625C8D_2001_6" unitRef="iso4217_USD">1783000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE730401--1410-Q0009_STD_0_20131231_0_1272289x1278641_1275669x1277587" decimals="-3" id="id_4670348_166BB6AA-3B56-4FA8-8087-B1DC27625C8D_3001_5" unitRef="iso4217_USD">45268000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AvailableForSaleSecurities contextRef="eol_PE730401--1410-Q0009_STD_0_20131231_0_1272289x1278641_1276335x1276695" decimals="-3" id="id_4670348_166BB6AA-3B56-4FA8-8087-B1DC27625C8D_4001_7" unitRef="iso4217_USD">23988000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:AvailableForSaleSecurities contextRef="eol_PE730401--1410-Q0009_STD_0_20131231_0_1280806x1270387" decimals="-3" id="id_4670348_9921B936-6F4D-45D3-958B-B72AA71276A6_4_4" unitRef="iso4217_USD">1783000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="eol_PE730401--1410-Q0009_STD_0_20131231_0_1280806x1270387" decimals="-3" id="id_4670348_9921B936-6F4D-45D3-958B-B72AA71276A6_4_1" unitRef="iso4217_USD">1784000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
  <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="eol_PE730401--1410-Q0009_STD_0_20131231_0_1280806x1270387" decimals="-3" id="id_4670348_9921B936-6F4D-45D3-958B-B72AA71276A6_4_3" unitRef="iso4217_USD">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
  <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="eol_PE730401--1410-Q0009_STD_0_20131231_0_1280806x1276695" decimals="-3" id="id_4670348_9921B936-6F4D-45D3-958B-B72AA71276A6_5_2" unitRef="iso4217_USD">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
  <us-gaap:AvailableForSaleSecurities contextRef="eol_PE730401--1410-Q0009_STD_0_20131231_0_1280806x1276695" decimals="-3" id="id_4670348_9921B936-6F4D-45D3-958B-B72AA71276A6_5_4" unitRef="iso4217_USD">23988000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="eol_PE730401--1410-Q0009_STD_0_20131231_0_1280806x1276695" decimals="-3" id="id_4670348_9921B936-6F4D-45D3-958B-B72AA71276A6_5_1" unitRef="iso4217_USD">23987000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
  <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="eol_PE730401--1410-Q0009_STD_0_20131231_0_1280806x1276695" decimals="-3" id="id_4670348_9921B936-6F4D-45D3-958B-B72AA71276A6_5_3" unitRef="iso4217_USD">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized contextRef="eol_PE730401--1410-Q0009_STD_1_20140325_0_1280964x1326831" decimals="INF" id="id_4670348_6B71623E-F724-4F57-96CB-8B93E7BF8572_1001_0" unitRef="shares">749017</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
  <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 contextRef="eol_PE730401--1410-Q0009_STD_1_20130925_0" decimals="2" id="id_4670348_DA50667F-C395-423F-80EC-AA272DDC27BE_1_4" unitRef="pure">2.62</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
  <us-gaap:ConversionOfStockSharesIssued1 contextRef="eol_PE730401--1410-Q0009_STD_1_20130925_0" decimals="INF" id="id_4670348_DA50667F-C395-423F-80EC-AA272DDC27BE_1_5" unitRef="shares">8515439</us-gaap:ConversionOfStockSharesIssued1>
  <us-gaap:ProceedsFromIssuanceInitialPublicOffering contextRef="eol_PE730401--1410-Q0009_STD_1_20130925_0" decimals="-5" id="id_4670348_DA50667F-C395-423F-80EC-AA272DDC27BE_1_2" unitRef="iso4217_USD">65600000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE730401--1410-Q0009_STD_1_20130925_0_1271382x1272538" decimals="INF" id="id_4670348_DA50667F-C395-423F-80EC-AA272DDC27BE_1001_0" unitRef="shares">4700000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="eol_PE730401--1410-Q0009_STD_1_20131023_0" decimals="-5" id="id_4670348_DA50667F-C395-423F-80EC-AA272DDC27BE_3_7" unitRef="iso4217_USD">5200000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE730401--1410-Q0009_STD_1_20131023_0_1271382x1272538" decimals="INF" id="id_4670348_DA50667F-C395-423F-80EC-AA272DDC27BE_1003_0" unitRef="shares">370499</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="eol_PE730401--1410-Q0009_STD_273_20130930_0" decimals="-3" id="id_4670348_B3537E10-5158-4A83-93D5-A92106642A08_2_12" unitRef="iso4217_USD">-7196000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="eol_PE730401--1410-Q0009_STD_273_20130930_0" decimals="0" id="id_4670348_DB100B7A-9F91-4F86-937E-D3A11E8F06D2_4_16" unitRef="shares">2595406</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE730401--1410-Q0009_STD_273_20130930_0" decimals="2" id="id_4670348_DB100B7A-9F91-4F86-937E-D3A11E8F06D2_4_14" unitRef="iso4217_USD_per_shares">-8.97</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:RevenueFromGrants contextRef="eol_PE730401--1410-Q0009_STD_273_20130930_0" decimals="-3" id="id_4670348_D9FA225F-6D99-4C5D-B451-F03E65B46305_4_0" unitRef="iso4217_USD">516000</us-gaap:RevenueFromGrants>
  <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="eol_PE730401--1410-Q0009_STD_273_20130930_0" decimals="-3" id="id_4670348_DBE2D5B3-EBC6-464B-B7BC-30D3DADAFE8D_4_2" unitRef="iso4217_USD">-235000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
  <us-gaap:RepaymentsOfLongTermCapitalLeaseObligations contextRef="eol_PE730401--1410-Q0009_STD_273_20130930_0" decimals="-3" id="id_4670348_B3537E10-5158-4A83-93D5-A92106642A08_2_26" unitRef="iso4217_USD">38000</us-gaap:RepaymentsOfLongTermCapitalLeaseObligations>
  <us-gaap:RepaymentsOfLongTermLinesOfCredit contextRef="eol_PE730401--1410-Q0009_STD_273_20130930_0" decimals="-3" id="id_4670348_B3537E10-5158-4A83-93D5-A92106642A08_2_28" unitRef="iso4217_USD">3326000</us-gaap:RepaymentsOfLongTermLinesOfCredit>
  <us-gaap:MarketableSecuritiesRealizedGainLoss contextRef="eol_PE730401--1410-Q0009_STD_273_20130930_0" decimals="INF" id="id_4670348_DAE93F34-720D-43E9-9828-5829AE57083D_4_1" unitRef="iso4217_USD">0</us-gaap:MarketableSecuritiesRealizedGainLoss>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="eol_PE730401--1410-Q0009_STD_273_20130930_0" decimals="-3" id="id_4670348_B3537E10-5158-4A83-93D5-A92106642A08_2_9" unitRef="iso4217_USD">870000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE730401--1410-Q0009_STD_273_20130930_0" decimals="-3" id="id_4670348_DB100B7A-9F91-4F86-937E-D3A11E8F06D2_4_5" unitRef="iso4217_USD">-18830000</us-gaap:OperatingIncomeLoss>
  <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="eol_PE730401--1410-Q0009_STD_273_20130930_0" decimals="-3" id="id_4670348_DB100B7A-9F91-4F86-937E-D3A11E8F06D2_4_7" unitRef="iso4217_USD">-606000</us-gaap:InterestIncomeExpenseNonoperatingNet>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="eol_PE730401--1410-Q0009_STD_273_20130930_0" decimals="-3" id="id_4670348_DBE2D5B3-EBC6-464B-B7BC-30D3DADAFE8D_4_4" unitRef="iso4217_USD">-19821000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:NonoperatingIncomeExpense contextRef="eol_PE730401--1410-Q0009_STD_273_20130930_0" decimals="-3" id="id_4670348_DB100B7A-9F91-4F86-937E-D3A11E8F06D2_4_9" unitRef="iso4217_USD">-756000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:PaymentsForProceedsFromOtherInvestingActivities contextRef="eol_PE730401--1410-Q0009_STD_273_20130930_0" decimals="-3" id="id_4670348_B3537E10-5158-4A83-93D5-A92106642A08_2_19" unitRef="iso4217_USD">-77000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="eol_PE730401--1410-Q0009_STD_273_20130930_0" decimals="-3" id="id_4670348_DB100B7A-9F91-4F86-937E-D3A11E8F06D2_4_8" unitRef="iso4217_USD">-150000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:Revenues contextRef="eol_PE730401--1410-Q0009_STD_273_20130930_0" decimals="-3" id="id_4670348_DB100B7A-9F91-4F86-937E-D3A11E8F06D2_4_0" unitRef="iso4217_USD">8831000</us-gaap:Revenues>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="eol_PE730401--1410-Q0009_STD_273_20130930_0" decimals="-3" id="id_4670348_B3537E10-5158-4A83-93D5-A92106642A08_2_14" unitRef="iso4217_USD">1826000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:OtherNoncashIncomeExpense contextRef="eol_PE730401--1410-Q0009_STD_273_20130930_0" decimals="-3" id="id_4670348_B3537E10-5158-4A83-93D5-A92106642A08_2_6" unitRef="iso4217_USD">-93000</us-gaap:OtherNoncashIncomeExpense>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="eol_PE730401--1410-Q0009_STD_273_20130930_0" decimals="-3" id="id_4670348_DB100B7A-9F91-4F86-937E-D3A11E8F06D2_4_12" unitRef="iso4217_USD">-23290000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:NetIncomeLoss contextRef="eol_PE730401--1410-Q0009_STD_273_20130930_0" decimals="-3" id="id_4670348_DB100B7A-9F91-4F86-937E-D3A11E8F06D2_4_10" unitRef="iso4217_USD">-19586000</us-gaap:NetIncomeLoss>
  <us-gaap:InterestPaid contextRef="eol_PE730401--1410-Q0009_STD_273_20130930_0" decimals="-3" id="id_4670348_B3537E10-5158-4A83-93D5-A92106642A08_2_40" unitRef="iso4217_USD">309000</us-gaap:InterestPaid>
  <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="eol_PE730401--1410-Q0009_STD_273_20130930_0" decimals="-3" id="id_4670348_B3537E10-5158-4A83-93D5-A92106642A08_2_8" unitRef="iso4217_USD">1384000</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="eol_PE730401--1410-Q0009_STD_273_20130930_0" decimals="-3" id="id_4670348_B3537E10-5158-4A83-93D5-A92106642A08_2_35" unitRef="iso4217_USD">160000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
  <us-gaap:DepreciationDepletionAndAmortization contextRef="eol_PE730401--1410-Q0009_STD_273_20130930_0" decimals="-3" id="id_4670348_B3537E10-5158-4A83-93D5-A92106642A08_2_3" unitRef="iso4217_USD">1041000</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="eol_PE730401--1410-Q0009_STD_273_20130930_0" decimals="-3" id="id_4670348_B3537E10-5158-4A83-93D5-A92106642A08_2_11" unitRef="iso4217_USD">7305000</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:OperatingExpenses contextRef="eol_PE730401--1410-Q0009_STD_273_20130930_0" decimals="-3" id="id_4670348_DB100B7A-9F91-4F86-937E-D3A11E8F06D2_4_4" unitRef="iso4217_USD">27661000</us-gaap:OperatingExpenses>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE730401--1410-Q0009_STD_273_20130930_0" decimals="-3" id="id_4670348_DB100B7A-9F91-4F86-937E-D3A11E8F06D2_4_2" unitRef="iso4217_USD">16965000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:EffectOfExchangeRateOnCash contextRef="eol_PE730401--1410-Q0009_STD_273_20130930_0" decimals="-3" id="id_4670348_B3537E10-5158-4A83-93D5-A92106642A08_2_30" unitRef="iso4217_USD">-26000</us-gaap:EffectOfExchangeRateOnCash>
  <us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations contextRef="eol_PE730401--1410-Q0009_STD_273_20130930_0" decimals="INF" id="id_4670348_F5546513-4A39-4E4B-9C34-956EA3533939_2_0" unitRef="iso4217_USD">0</us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="eol_PE730401--1410-Q0009_STD_273_20130930_0" decimals="-3" id="id_4670348_B3537E10-5158-4A83-93D5-A92106642A08_2_31" unitRef="iso4217_USD">75829000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:FairValueAdjustmentOfWarrants contextRef="eol_PE730401--1410-Q0009_STD_273_20130930_0" decimals="-3" id="id_4670348_B3537E10-5158-4A83-93D5-A92106642A08_2_5" unitRef="iso4217_USD">273000</us-gaap:FairValueAdjustmentOfWarrants>
  <us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment contextRef="eol_PE730401--1410-Q0009_STD_273_20130930_0" decimals="-3" id="id_4670348_DB100B7A-9F91-4F86-937E-D3A11E8F06D2_4_11" unitRef="iso4217_USD">3704000</us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="eol_PE730401--1410-Q0009_STD_273_20130930_0" decimals="-3" id="id_4670348_B3537E10-5158-4A83-93D5-A92106642A08_2_29" unitRef="iso4217_USD">84088000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="eol_PE730401--1410-Q0009_STD_273_20130930_0" decimals="-3" id="id_4670348_B3537E10-5158-4A83-93D5-A92106642A08_2_25" unitRef="iso4217_USD">228000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations contextRef="eol_PE730401--1410-Q0009_STD_273_20130930_0" decimals="INF" id="id_4670348_F5546513-4A39-4E4B-9C34-956EA3533939_2_1" unitRef="iso4217_USD">0</us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations>
  <us-gaap:TemporaryEquityDividendsAdjustment contextRef="eol_PE730401--1410-Q0009_STD_273_20130930_0" decimals="-3" id="id_4670348_B37D91D9-3818-4BE8-B04C-25E44F2B6FC4_4_2" unitRef="iso4217_USD">3396000</us-gaap:TemporaryEquityDividendsAdjustment>
  <us-gaap:ConversionOfStockAmountConverted1 contextRef="eol_PE730401--1410-Q0009_STD_273_20130930_0" decimals="-3" id="id_4670348_B3537E10-5158-4A83-93D5-A92106642A08_2_38" unitRef="iso4217_USD">83515000</us-gaap:ConversionOfStockAmountConverted1>
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="eol_PE730401--1410-Q0009_STD_273_20130930_0" decimals="-3" id="id_4670348_B3537E10-5158-4A83-93D5-A92106642A08_2_20" unitRef="iso4217_USD">-1037000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE730401--1410-Q0009_STD_273_20130930_0" decimals="-3" id="id_4670348_DB100B7A-9F91-4F86-937E-D3A11E8F06D2_4_3" unitRef="iso4217_USD">10696000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="eol_PE730401--1410-Q0009_STD_273_20130930_0" decimals="-3" id="id_4670348_B3537E10-5158-4A83-93D5-A92106642A08_2_10" unitRef="iso4217_USD">737000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:ProceedsFromIssuanceInitialPublicOffering contextRef="eol_PE730401--1410-Q0009_STD_273_20130930_0" decimals="-3" id="id_4670348_B3537E10-5158-4A83-93D5-A92106642A08_2_24" unitRef="iso4217_USD">63942000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
  <us-gaap:ProceedsFromLongTermLinesOfCredit contextRef="eol_PE730401--1410-Q0009_STD_273_20130930_0" decimals="-3" id="id_4670348_B3537E10-5158-4A83-93D5-A92106642A08_2_27" unitRef="iso4217_USD">4500000</us-gaap:ProceedsFromLongTermLinesOfCredit>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE730401--1410-Q0009_STD_273_20130930_0" decimals="-3" id="id_4670348_B3537E10-5158-4A83-93D5-A92106642A08_2_4" unitRef="iso4217_USD">5195000</us-gaap:ShareBasedCompensation>
  <us-gaap:MarketableSecuritiesRealizedGainLossOtherThanTemporaryImpairmentsAmount contextRef="eol_PE730401--1410-Q0009_STD_273_20130930_0" decimals="INF" id="id_4670348_DAE93F34-720D-43E9-9828-5829AE57083D_4_2" unitRef="iso4217_USD">0</us-gaap:MarketableSecuritiesRealizedGainLossOtherThanTemporaryImpairmentsAmount>
  <bind:ProceedsFromRepaymentOfStockholderLoans contextRef="eol_PE730401--1410-Q0009_STD_273_20130930_0" decimals="-3" id="id_4670348_B3537E10-5158-4A83-93D5-A92106642A08_2_18" unitRef="iso4217_USD">712000</bind:ProceedsFromRepaymentOfStockholderLoans>
  <bind:InitialPublicOfferingCostIncurredDuringNoncashOrPartialNoncashTransaction contextRef="eol_PE730401--1410-Q0009_STD_273_20130930_0" decimals="-3" id="id_4670348_B3537E10-5158-4A83-93D5-A92106642A08_2_39" unitRef="iso4217_USD">1418000</bind:InitialPublicOfferingCostIncurredDuringNoncashOrPartialNoncashTransaction>
  <bind:AccretionOfPreferredStockIssuanceCostsToRedemptionValue contextRef="eol_PE730401--1410-Q0009_STD_273_20130930_0" decimals="-3" id="id_4670348_B37D91D9-3818-4BE8-B04C-25E44F2B6FC4_4_1" unitRef="iso4217_USD">308000</bind:AccretionOfPreferredStockIssuanceCostsToRedemptionValue>
  <bind:ProceedsFromGrants contextRef="eol_PE730401--1410-Q0009_STD_273_20130930_0" decimals="-5" id="id_4670348_5F0954C3-DC3B-4A43-A300-67705006E574_4_0" unitRef="iso4217_RUB">19900000</bind:ProceedsFromGrants>
  <bind:ProceedsFromGrants contextRef="eol_PE730401--1410-Q0009_STD_273_20130930_0" decimals="-5" id="id_4670348_5F0954C3-DC3B-4A43-A300-67705006E574_6_0" unitRef="iso4217_USD">600000</bind:ProceedsFromGrants>
  <bind:ResearchAndDevelopmentCollaborationAgreementRevenue contextRef="eol_PE730401--1410-Q0009_STD_273_20130930_0" decimals="-3" id="id_4670348_D9FA225F-6D99-4C5D-B451-F03E65B46305_4_1" unitRef="iso4217_USD">8315000</bind:ResearchAndDevelopmentCollaborationAgreementRevenue>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE730401--1410-Q0009_STD_273_20130930_0_1268687x1271210" decimals="INF" id="id_4670348_F63211FA-4135-41EF-B531-8D9E7B2CC12D_1002_2" unitRef="shares">67787</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE730401--1410-Q0009_STD_273_20130930_0_1268687x1273442" decimals="INF" id="id_4670348_F63211FA-4135-41EF-B531-8D9E7B2CC12D_2002_1" unitRef="shares">74412</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE730401--1410-Q0009_STD_273_20130930_0_1268687x1275629" decimals="INF" id="id_4670348_F63211FA-4135-41EF-B531-8D9E7B2CC12D_3002_0" unitRef="shares">2182721</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:DeferredRevenueRevenueRecognized contextRef="eol_PE730401--1410-Q0009_STD_273_20130930_0_1272072x1314996" decimals="-5" id="id_4670348_ED12A3E8-4383-4C29-8FDB-2DF3A8428EF4_1005_2" unitRef="iso4217_USD">3900000</us-gaap:DeferredRevenueRevenueRecognized>
  <us-gaap:DeferredRevenueRevenueRecognized contextRef="eol_PE730401--1410-Q0009_STD_273_20130930_0_1272072x1367107" decimals="-5" id="id_4670348_52F36303-2E76-4586-A3E2-681220880A58_1004_0" unitRef="iso4217_USD">1900000</us-gaap:DeferredRevenueRevenueRecognized>
  <us-gaap:DeferredRevenueRevenueRecognized contextRef="eol_PE730401--1410-Q0009_STD_273_20130930_0_1272072x1545620" decimals="-5" id="id_4670348_65524187-74EE-48E7-A63D-F61D3DA4864A_1004_0" unitRef="iso4217_USD">2100000</us-gaap:DeferredRevenueRevenueRecognized>
  <us-gaap:RevenueFromGrants contextRef="eol_PE730401--1410-Q0009_STD_273_20130930_0_1272072x1592869_1273333x1278099" decimals="-5" id="id_4670348_5F0954C3-DC3B-4A43-A300-67705006E574_1006_1" unitRef="iso4217_USD">500000</us-gaap:RevenueFromGrants>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="eol_PE730401--1410-Q0009_STD_273_20130930_0_1273383x1448784" decimals="INF" id="id_4670348_727810A8-253A-474F-8A13-6E9F9637AAF8_1002_3" unitRef="shares">134439</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="eol_PE730401--1410-Q0009_STD_273_20130930_0_1273383x1502643" decimals="INF" id="id_4670348_727810A8-253A-474F-8A13-6E9F9637AAF8_2002_2" unitRef="shares">159917</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE730401--1410-Q0009_STD_273_20130930_0_1274159x1269133" decimals="-3" id="id_4670348_6D77B0DA-1186-42D9-8241-0E457372E26C_1004_1" unitRef="iso4217_USD">4037000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE730401--1410-Q0009_STD_273_20130930_0_1274159x1269570" decimals="-3" id="id_4670348_6D77B0DA-1186-42D9-8241-0E457372E26C_2004_0" unitRef="iso4217_USD">1158000</us-gaap:ShareBasedCompensation>
  <us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock contextRef="eol_PE730401--1410-Q0009_STD_273_20130930_0_1276400x1281158" decimals="-3" id="id_4670348_B3537E10-5158-4A83-93D5-A92106642A08_1002_22" unitRef="iso4217_USD">17282000</us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock>
  <us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock contextRef="eol_PE730401--1410-Q0009_STD_273_20130930_0_1276400x1554438" decimals="-3" id="id_4670348_B3537E10-5158-4A83-93D5-A92106642A08_2002_23" unitRef="iso4217_USD">1500000</us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock>
  <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="eol_PE730401--1410-Q0009_STD_273_20140930_0" id="id_4670348_4219892A-6D88-4B4F-8E1B-9988CEAE1843_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;6. ACCRUED EXPENSES&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 Accrued expenses as of September&amp;#xA0;30, 2014, and
 December&amp;#xA0;31, 2013, consisted of the following (in
 thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="92%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;As&amp;#xA0;of&amp;#xA0;September&amp;#xA0;30,&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;As&amp;#xA0;of&amp;#xA0;December&amp;#xA0;31,&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Accrued compensation and benefits&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,365&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;612&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Accrued clinical trial costs&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,029&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;709&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Other accrued expenses&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,782&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,087&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Total accrued expenses&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,176&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,408&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;


 &lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
  <us-gaap:AvailableForSaleSecuritiesTextBlock contextRef="eol_PE730401--1410-Q0009_STD_273_20140930_0" id="id_4670348_4F4CBAD9-6187-496B-AEC5-883AB5CF46B9_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 The following is a summary of marketable securities (included in
 short and long-term investments in the Condensed Consolidated
 Balance Sheets) as of September&amp;#xA0;30, 2014 and December&amp;#xA0;31,
 2013 (in thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="87%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Amortized&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Cost&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Gross&amp;#xA0;Unrealized&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Gains&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Gross&amp;#xA0;Unrealized&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Losses&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Fair&amp;#xA0;Value&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 &lt;b&gt;&lt;u&gt;September&amp;#xA0;30, 2014&lt;/u&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Certificates of deposit&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9,900&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(7&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9,893&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 U.S. government agency notes&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;17,255&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;17,259&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;27,155&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(7&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;27,152&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 &lt;b&gt;&lt;u&gt;December&amp;#xA0;31, 2013&lt;/u&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Certificates of deposit&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,784&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(1&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,783&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 U.S. government agency notes&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;23,987&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(2&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;23,988&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;25,771&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(3&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;25,771&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;


 &lt;/div&gt;</us-gaap:AvailableForSaleSecuritiesTextBlock>
  <us-gaap:CommitmentsDisclosureTextBlock contextRef="eol_PE730401--1410-Q0009_STD_273_20140930_0" id="id_4670348_F67F7EEF-44BF-45F5-9902-EDAB4B93A76A_1_0">&lt;div&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;10. COMMITMENTS&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 In June 2014, we amended our primary office and laboratory lease.
 The amendment added space in the same building that we had been
 subleasing from a third party into our office and laboratory lease
 which continues through April 2017. The amendment did not result in
 material changes to our rent expense or deferred rent amounts.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:CommitmentsDisclosureTextBlock>
  <us-gaap:EarningsPerShareTextBlock contextRef="eol_PE730401--1410-Q0009_STD_273_20140930_0" id="id_4670348_F857F1B0-CC22-44EE-9427-5FA00D634B29_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 50px; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;2. NET LOSS PER SHARE ATTRIBUTABLE TO COMMON
 STOCKHOLDERS&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 The following table summarizes the computation of basic and diluted
 net loss per share attributable to our common stockholders (in
 thousands, except share and per share data):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="84%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"&gt;
 &lt;b&gt;Three&amp;#xA0;Months&amp;#xA0;Ended&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;September 30,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;Nine&amp;#xA0;Months&amp;#xA0;Ended&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;September 30,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Net loss&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(7,277&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(7,378&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(24,043&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(19,586&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Accretion of preferred stock issuance costs to redemption value&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(74&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(308&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Accrued dividends on redeemable convertible preferred stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(883&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(3,396&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Net loss attributable to common stockholders&amp;#x2014;basic and
 diluted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(7,277&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(8,335&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(24,043&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(23,290&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Weighted-average number of common shares&amp;#x2014;basic and
 diluted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;16,544,402&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,391,239&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;16,477,974&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,595,406&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Net loss per share attributable to common stockholders&amp;#x2014;basic
 and diluted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.44&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(2.46&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(1.46&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(8.97&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 Because we have reported a net loss for all periods presented,
 diluted net loss per common share is the same as basic net loss per
 common share.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 The following potentially dilutive securities outstanding, prior to
 the use of the treasury stock method or if-converted method, have
 been excluded from the computation of diluted weighted-average
 shares outstanding, because such securities had an antidilutive
 impact due to the losses reported:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="92%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;As of&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;September&amp;#xA0;30,&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;September&amp;#xA0;30,&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Options to purchase common stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,593,012&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,182,721&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Warrants to purchase common stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;74,412&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;74,412&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Unvested restricted stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;67,787&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;br class="Apple-interchange-newline" /&gt;

 &lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
  <dei:DocumentType contextRef="eol_PE730401--1410-Q0009_STD_273_20140930_0" id="id_4670348_855E51D5-716C-4D8F-B578-A1152CA9D234_1_0">10-Q</dei:DocumentType>
  <dei:EntityRegistrantName contextRef="eol_PE730401--1410-Q0009_STD_273_20140930_0" id="id_4670348_F291F981-BC86-47D2-BE8C-679D8B7E44CF_1_1">BIND Therapeutics, Inc.</dei:EntityRegistrantName>
  <dei:TradingSymbol contextRef="eol_PE730401--1410-Q0009_STD_273_20140930_0" id="id_4670348_F291F981-BC86-47D2-BE8C-679D8B7E44CF_1_0">BIND</dei:TradingSymbol>
  <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock contextRef="eol_PE730401--1410-Q0009_STD_273_20140930_0" id="id_4670348_1517B80B-587C-4149-82D6-6CB0C18DD6B0_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 The following table provides the assets carried at fair value
 measured on a recurring basis as of September&amp;#xA0;30, 2014, and
 December&amp;#xA0;31, 2013 (in thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="84%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="10" align="center"&gt;&lt;b&gt;Fair Value Measurements
 Using&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Carrying&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Value&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Quoted&amp;#xA0;Prices&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;in Active&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Markets for&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Identical&amp;#xA0;Assets&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;(Level 1)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Significant&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;other&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Observable&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Inputs&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;(Level 2)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Significant&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Unobservable&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Inputs&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;(Level 3)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 &lt;b&gt;&lt;u&gt;September&amp;#xA0;30, 2014&lt;/u&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Money market funds(1)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;19,625&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;19,625&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Certificates of deposit(2)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9,893&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9,893&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 U.S. government agency notes(2)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;17,259&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;17,259&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;46,777&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;19,625&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;27,152&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 &lt;b&gt;&lt;u&gt;December&amp;#xA0;31, 2013&lt;/u&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Money market funds(1)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;45,268&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;45,268&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Certificates of deposit(2)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,783&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,783&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 U.S. government agency notes(2)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;23,988&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;23,988&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;71,039&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;45,268&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;25,771&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 2pt; WHITE-SPACE: normal; BORDER-BOTTOM: rgb(0,0,0) 1px solid; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: medium/8pt 'Times New Roman'; MARGIN-TOP: 0pt; LETTER-SPACING: normal; WIDTH: 103px; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr&gt;
 &lt;td valign="top" width="4%" align="left"&gt;(1)&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;Money market funds are included
 within cash and cash equivalents and restricted cash in the
 accompanying Condensed Consolidated Balance Sheets.&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr&gt;
 &lt;td valign="top" width="4%" align="left"&gt;(2)&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;Certificates of deposit and U.S.
 government agency notes are included within short-term investments
 and long-term investments in the accompanying Condensed
 Consolidated Balance Sheets.&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;


 &lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
  <us-gaap:InvestmentPolicyTextBlock contextRef="eol_PE730401--1410-Q0009_STD_273_20140930_0" id="id_4670348_4E25FB93-CACF-4F32-8396-50C65A7B48D6_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Short-term and long-term investments represent holdings of
 available-for-sale marketable securities in accordance with our
 investment policy and cash management strategy. Short-term
 investments mature within 12 months from the balance sheet date and
 long-term marketable securities represent investments with maturity
 dates greater than one year from the balance sheet date. At the
 time that the maturity dates of these investments become one year
 or less, the securities are reclassified as short-term investments.
 Our investments in marketable securities are recorded at fair
 value, with any unrealized gains and losses, net of taxes, reported
 as a component of stockholders&amp;#x2019; equity until realized or
 until a determination is made that an other-than-temporary decline
 in market value has occurred. The cost of marketable securities
 sold is determined based on the specific identification method and
 any realized gains or losses on the sale of investments are
 reflected as a component of interest income (expense), net.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:InvestmentPolicyTextBlock>
  <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="eol_PE730401--1410-Q0009_STD_273_20140930_0" id="id_4670348_2EBF53A0-0AA4-4775-9C47-29FB50BFD72E_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 The following potentially dilutive securities outstanding, prior to
 the use of the treasury stock method or if-converted method, have
 been excluded from the computation of diluted weighted-average
 shares outstanding, because such securities had an antidilutive
 impact due to the losses reported:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="92%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;As of&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;September&amp;#xA0;30,&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;September&amp;#xA0;30,&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Options to purchase common stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,593,012&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,182,721&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Warrants to purchase common stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;74,412&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;74,412&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Unvested restricted stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;67,787&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;br class="Apple-interchange-newline" /&gt;

 &lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="eol_PE730401--1410-Q0009_STD_273_20140930_0" decimals="2" id="id_4670348_727810A8-253A-474F-8A13-6E9F9637AAF8_1_1" unitRef="iso4217_USD_per_shares">8.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <dei:EntityFilerCategory contextRef="eol_PE730401--1410-Q0009_STD_273_20140930_0" id="id_4670348_F291F981-BC86-47D2-BE8C-679D8B7E44CF_1_4">Non-accelerated Filer</dei:EntityFilerCategory>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="eol_PE730401--1410-Q0009_STD_273_20140930_0" id="id_4670348_112C7D26-7FF2-48B7-BF3E-7F5D08A14E18_1_1">P3Y1M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="eol_PE730401--1410-Q0009_STD_273_20140930_0" decimals="-3" id="id_4670348_B3537E10-5158-4A83-93D5-A92106642A08_1_12" unitRef="iso4217_USD">-21968000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock contextRef="eol_PE730401--1410-Q0009_STD_273_20140930_0" id="id_4670348_BE8A8698-76D7-4443-B12E-D5C2CBB14788_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;1. NATURE OF BUSINESS AND BASIS OF PRESENTATION&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 BIND Therapeutics,&amp;#xA0;Inc. is a clinical-stage nanomedicine
 platform company developing Accurins, targeted and programmable
 therapeutics. As used throughout these condensed consolidated
 financial statements, the terms &amp;#x201C;BIND,&amp;#x201D;
 &amp;#x201C;we,&amp;#x201D; &amp;#x201C;us,&amp;#x201D; and &amp;#x201C;our&amp;#x201D; refer to
 the business of BIND Therapeutics, Inc. including our wholly-owned
 subsidiaries, BIND (RUS) LLC and BIND Biosciences Security
 Corporation. Our strategy is to leverage our Medicinal
 Nanoengineering&amp;#xAE; platform to develop our own pipeline of
 Accurins, initially in oncology, as well as to develop Accurins in
 collaboration with biopharmaceutical companies.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 Our success is dependent upon our ability to successfully complete
 clinical development of and obtain regulatory approval of our drug
 candidates; successfully commercialize any approved products;
 generate revenue; meet our obligations; maintain adequate
 financing; and, ultimately, attain profitable operations.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 The unaudited condensed consolidated financial statements have been
 prepared on the same basis as the audited consolidated financial
 statements. In the opinion of our management, the accompanying
 unaudited condensed consolidated financial statements contain all
 adjustments which are necessary to present fairly our financial
 position as of September&amp;#xA0;30, 2014, the results of our
 operations for the three and nine months ended September&amp;#xA0;30,
 2014 and 2013, and cash flows for the nine months ended
 September&amp;#xA0;30, 2014 and 2013. Such adjustments are of a normal
 and recurring nature. The results for the three and nine months
 ended September&amp;#xA0;30, 2014 are not indicative of the results for
 the year ending December&amp;#xA0;31, 2014, or for any future
 period.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 On September&amp;#xA0;25, 2013, we completed an initial public offering
 (&amp;#x201C;IPO&amp;#x201D;) of our common stock, which resulted in the sale
 of 4,700,000 shares, at a price of $15.00 per share. We received
 net proceeds before expenses from the IPO of $65.6 million after
 deducting underwriting discounts and commissions paid by us. In
 preparation for the IPO, our Board of Directors and stockholders
 approved a 1:2.62 reverse stock split of our common stock effective
 September&amp;#xA0;5, 2013. All share and per share amounts in the
 unaudited condensed consolidated financial statements and notes
 thereto have been retroactively adjusted, where necessary, to give
 effect to this reverse stock split. In connection with the closing
 of the IPO, all of our outstanding redeemable convertible preferred
 stock automatically converted to common stock at a 1:2.62 ratio on
 September&amp;#xA0;25, 2013, resulting in an additional 8,515,439
 shares of our common stock becoming outstanding. On
 October&amp;#xA0;18, 2013, the underwriters exercised in part their
 option to purchase additional shares pursuant to the underwriting
 agreement relating to our IPO. On October&amp;#xA0;23, 2013, we closed
 a portion of the underwriters&amp;#x2019; over-allotment option, and we
 sold an additional 370,499 shares at a price to the public of
 $15.00 per share. We received net proceeds before expenses of
 approximately $5.2 million after deducting underwriting discounts
 and commissions. The significant increase in the shares outstanding
 in September 2013 is expected to impact the comparability of our
 net loss per share calculations between 2013 and 2014 periods.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;Summary of Significant Accounting Policies&lt;/b&gt;&amp;#x2014;There have
 been no material changes to the significant accounting policies
 previously disclosed in our Annual Report on Form 10-K for the year
 ended December&amp;#xA0;31, 2013.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 On August&amp;#xA0;27, 2014, the Financial Accounting Standards Board
 (&amp;#x201C;FASB&amp;#x201D;) issued ASU 2014-15,&amp;#xA0;&lt;i&gt;Disclosure of Uncertainties
 about an Entity&amp;#x2019;s Ability to Continue as a Going
 Concern&lt;/i&gt;&amp;#xA0;(&amp;#x201C;ASU 2014-15&amp;#x201D;),
 which provides guidance on determining when and how to disclose
 going-concern uncertainties in the financial statements. The new
 standard requires management to perform interim and annual
 assessments of an entity&amp;#x2019;s ability to continue as a going
 concern within one year of the date the financial statements are
 issued. An entity must provide certain disclosures if
 &amp;#x201C;conditions or events raise substantial doubt about the
 entity&amp;#x2019;s ability to continue as a going concern.&amp;#x201D; ASU
 2014-15 is effective for us on January&amp;#xA0;1, 2017, with early
 adoption permitted. We are currently assessing the potential impact
 of the adoption of ASU 2014-15 on our condensed consolidated
 financial statements.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 On May&amp;#xA0;28, 2014, the FASB issued ASU 2014-09,&amp;#xA0;&lt;i&gt;Revenue from Contracts with
 Customers&lt;/i&gt;&amp;#xA0;(&amp;#x201C;ASU 2014-09&amp;#x201D;),
 its final standard on revenue from contracts with customers. ASU
 2014-09 outlines a single comprehensive model for entities to use
 in accounting for revenue arising from contracts with customers and
 supersedes most current revenue recognition guidance, including
 industry-specific guidance. The core principle of the revenue model
 is that an entity recognizes revenue to depict the transfer of
 promised goods or services to customers in an amount that reflects
 the consideration to which the entity expects to be entitled in
 exchange for those goods or services. In applying the revenue model
 to contracts within its scope, an entity identifies the contract(s)
 with a customer, identifies the performance obligations in the
 contract, determines the transaction price, allocates the
 transaction price to the performance obligations in the contract
 and recognizes revenue when (or as) the entity satisfies a
 performance obligation. ASU 2014-09 also requires significantly
 expanded disclosures about revenue recognition. ASU 2014-09 is
 effective for us on January&amp;#xA0;1, 2017. We are currently
 assessing the potential impact of the adoption of ASU 2014-09 on
 our condensed consolidated financial statements.&lt;/p&gt;


 &lt;/div&gt;</us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock>
  <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="eol_PE730401--1410-Q0009_STD_273_20140930_0" id="id_4670348_60E0DDBB-FCC5-404E-BA78-DD29A14F6F64_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 We have recorded aggregate stock-based compensation expense related
 to the issuance of stock option awards in the following line items
 in the accompanying Condensed Consolidated Statements of Operations
 (in thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="73%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"&gt;
 &lt;b&gt;Three&amp;#xA0;Months&amp;#xA0;Ended&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;September 30,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;Nine&amp;#xA0;Months&amp;#xA0;Ended&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;September 30,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Research and development&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;209&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;534&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;983&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,158&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 General and administrative&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;378&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,786&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,062&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,037&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;587&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,320&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,045&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,195&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;br class="Apple-interchange-newline" /&gt;

 &lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
  <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="eol_PE730401--1410-Q0009_STD_273_20140930_0" id="id_4670348_58BEE1EF-5100-44C4-8F2D-D52C8A0A7C0F_1_0">&lt;div&gt;
 On May&amp;#xA0;28, 2014, the FASB issued ASU 2014-09,&amp;#xA0;&lt;i style="FONT-SIZE: 13px; FONT-FAMILY: 'Times New Roman'; FONT-VARIANT: normal; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); LETTER-SPACING: normal; LINE-HEIGHT: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;Revenue
 from Contracts with Customers&lt;/i&gt;&amp;#xA0;(&amp;#x201C;ASU
 2014-09&amp;#x201D;), its final standard on revenue from contracts with
 customers. ASU 2014-09 outlines a single comprehensive model for
 entities to use in accounting for revenue arising from contracts
 with customers and supersedes most current revenue recognition
 guidance, including industry-specific guidance. The core principle
 of the revenue model is that an entity recognizes revenue to depict
 the transfer of promised goods or services to customers in an
 amount that reflects the consideration to which the entity expects
 to be entitled in exchange for those goods or services. In applying
 the revenue model to contracts within its scope, an entity
 identifies the contract(s) with a customer, identifies the
 performance obligations in the contract, determines the transaction
 price, allocates the transaction price to the performance
 obligations in the contract and recognizes revenue when (or as) the
 entity satisfies a performance obligation. ASU 2014-09 also
 requires significantly expanded disclosures about revenue
 recognition. ASU 2014-09 is effective for us on January&amp;#xA0;1,
 2017. We are currently assessing the potential impact of the
 adoption of ASU 2014-09 on our condensed consolidated financial
 statements.&lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
  <us-gaap:StockholdersEquityReverseStockSplit contextRef="eol_PE730401--1410-Q0009_STD_273_20140930_0" id="id_4670348_DA50667F-C395-423F-80EC-AA272DDC27BE_2_3">Company&#x2019;s Board of Directors and stockholders approved a reverse stock split of the Company&#x2019;s common stock on a 1 for 2.62 basis.</us-gaap:StockholdersEquityReverseStockSplit>
  <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="eol_PE730401--1410-Q0009_STD_273_20140930_0" id="id_4670348_43A5B4F3-D290-47A8-B707-195CD1862B65_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 Accrued expenses as of September&amp;#xA0;30, 2014, and
 December&amp;#xA0;31, 2013, consisted of the following (in
 thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="92%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;As&amp;#xA0;of&amp;#xA0;September&amp;#xA0;30,&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;As&amp;#xA0;of&amp;#xA0;December&amp;#xA0;31,&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Accrued compensation and benefits&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,365&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;612&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Accrued clinical trial costs&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,029&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;709&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Other accrued expenses&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,782&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,087&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Total accrued expenses&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,176&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,408&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;br class="Apple-interchange-newline" /&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="eol_PE730401--1410-Q0009_STD_273_20140930_0" decimals="0" id="id_4670348_DB100B7A-9F91-4F86-937E-D3A11E8F06D2_3_16" unitRef="shares">16477974</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <dei:DocumentPeriodEndDate contextRef="eol_PE730401--1410-Q0009_STD_273_20140930_0" id="id_4670348_855E51D5-716C-4D8F-B578-A1152CA9D234_1_2">2014-09-30</dei:DocumentPeriodEndDate>
  <dei:AmendmentFlag contextRef="eol_PE730401--1410-Q0009_STD_273_20140930_0" id="id_4670348_855E51D5-716C-4D8F-B578-A1152CA9D234_1_1">false</dei:AmendmentFlag>
  <dei:CurrentFiscalYearEndDate contextRef="eol_PE730401--1410-Q0009_STD_273_20140930_0" id="id_4670348_F291F981-BC86-47D2-BE8C-679D8B7E44CF_1_3">--12-31</dei:CurrentFiscalYearEndDate>
  <dei:DocumentFiscalYearFocus contextRef="eol_PE730401--1410-Q0009_STD_273_20140930_0" id="id_4670348_855E51D5-716C-4D8F-B578-A1152CA9D234_1_3">2014</dei:DocumentFiscalYearFocus>
  <us-gaap:IncomeTaxDisclosureTextBlock contextRef="eol_PE730401--1410-Q0009_STD_273_20140930_0" id="id_4670348_B63485AC-7B55-48B6-B8B3-3421C50A959F_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;9. INCOME TAXES&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 We did not record a federal or state income tax benefit for our
 losses for the nine months ended September&amp;#xA0;30, 2014 and 2013
 due to our conclusion that a full valuation allowance is required
 against our deferred tax assets.&lt;/p&gt;


 &lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
  <us-gaap:LineOfCreditFacilityInterestRateDuringPeriod contextRef="eol_PE730401--1410-Q0009_STD_273_20140930_0" decimals="4" id="id_4670348_F42EDA83-2E23-4302-82F9-A31E62F850C3_1_0" unitRef="pure">0.1025</us-gaap:LineOfCreditFacilityInterestRateDuringPeriod>
  <us-gaap:LongTermDebtTextBlock contextRef="eol_PE730401--1410-Q0009_STD_273_20140930_0" id="id_4670348_E5C03C91-58C8-420F-B452-23CC76CD42C3_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;7. LONG-TERM DEBT&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 In June 2013, we amended and restated our credit facility with
 Hercules Technology Growth Capital, Inc. as lender to provide for
 borrowings of up to $8.5 million through December 2013. Upon
 closing in June 2013, we borrowed $4.5 million. The proceeds from
 the initial borrowing were used to pay off the outstanding balance
 of $2.3 million on our prior credit facility. We did not elect to
 fund the second advance as of December&amp;#xA0;31, 2013, and, as a
 result, the $4.0 million is no longer available to us. The
 amendment and pay off were accounted for as a debt extinguishment.
 There was no gain or loss associated with the extinguishment.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 Interest on the amended and restated credit facility accrues daily
 on the outstanding balance at a rate of 10.25% plus the prime rate
 less 3.25% (a minimum of 10.25%) and was payable monthly through
 February 2014. Beginning in March 2014, the loan principal and
 accrued interest are due in 30&amp;#xA0;equal monthly installments. The
 loan can be prepaid at any time with certain additional amounts due
 based on the date of the prepayment. The loan is secured by our
 tangible assets as of the date of the loan and additions acquired
 thereafter. The credit facility permits the lender to declare a
 default upon the occurrence of a material adverse event as defined.
 Under such default, all amounts outstanding under the credit
 facility would be payable immediately. The credit facility contains
 certain restrictions on additional indebtedness, stock repurchases,
 dividend payments and future loans. The total amount outstanding
 under these facilities as of September&amp;#xA0;30, 2014 and
 December&amp;#xA0;31, 2013 was $3.7 million and $4.5 million,
 respectively.&lt;/p&gt;


 &lt;/div&gt;</us-gaap:LongTermDebtTextBlock>
  <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="eol_PE730401--1410-Q0009_STD_273_20140930_0" id="id_4670348_9358F6AA-0DA5-48CE-A466-31ED9410DCA0_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 The following table summarizes the computation of basic and diluted
 net loss per share attributable to our common stockholders (in
 thousands, except share and per share data):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="84%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"&gt;
 &lt;b&gt;Three&amp;#xA0;Months&amp;#xA0;Ended&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;September 30,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;Nine&amp;#xA0;Months&amp;#xA0;Ended&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;September 30,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Net loss&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(7,277&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(7,378&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(24,043&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(19,586&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Accretion of preferred stock issuance costs to redemption value&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(74&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(308&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Accrued dividends on redeemable convertible preferred stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(883&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(3,396&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Net loss attributable to common stockholders&amp;#x2014;basic and
 diluted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(7,277&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(8,335&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(24,043&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(23,290&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Weighted-average number of common shares&amp;#x2014;basic and
 diluted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;16,544,402&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,391,239&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;16,477,974&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,595,406&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Net loss per share attributable to common stockholders&amp;#x2014;basic
 and diluted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.44&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(2.46&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(1.46&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(8.97&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;


 &lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="eol_PE730401--1410-Q0009_STD_273_20140930_0" id="id_4670348_727810A8-253A-474F-8A13-6E9F9637AAF8_1_4">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="eol_PE730401--1410-Q0009_STD_273_20140930_0" decimals="2" id="id_4670348_727810A8-253A-474F-8A13-6E9F9637AAF8_1_0" unitRef="iso4217_USD_per_shares">11.91</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:SubsequentEventsTextBlock contextRef="eol_PE730401--1410-Q0009_STD_273_20140930_0" id="id_4670348_EC5E3756-E877-4BC4-B20C-DD6123090E50_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;11. SUBSEQUENT EVENT&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 In October 2014, we entered into an at-the-market
 (&amp;#x201C;ATM&amp;#x201D;) sales facility pursuant to which we may, at our
 option, offer and sell shares of our common stock from time to time
 for an aggregate offering price of up to $40 million through Cowen
 and Company, LLC.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
  <dei:EntityCentralIndexKey contextRef="eol_PE730401--1410-Q0009_STD_273_20140930_0" id="id_4670348_F291F981-BC86-47D2-BE8C-679D8B7E44CF_1_2">0001385228</dei:EntityCentralIndexKey>
  <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="eol_PE730401--1410-Q0009_STD_273_20140930_0" id="id_4670348_31A03C55-D663-48F1-9054-0052F62D0DD3_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;8. STOCK-BASED COMPENSATION&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 We have recorded aggregate stock-based compensation expense related
 to the issuance of stock option awards in the following line items
 in the accompanying Condensed Consolidated Statements of Operations
 (in thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="73%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"&gt;
 &lt;b&gt;Three&amp;#xA0;Months&amp;#xA0;Ended&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;September 30,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;Nine&amp;#xA0;Months&amp;#xA0;Ended&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;September 30,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Research and development&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;209&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;534&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;983&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,158&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 General and administrative&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;378&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,786&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,062&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,037&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;587&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,320&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,045&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,195&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 41px; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;Stock Options&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 On March&amp;#xA0;25, 2014, we registered with the Securities Exchange
 Commission on Form S-8 an additional 749,017 shares of common stock
 to be issued pursuant to the 2013 Incentive Award Plan (&amp;#x201C;2013
 Plan&amp;#x201D;) evergreen provision. As of September&amp;#xA0;30, 2014,
 there were 1,562,671 shares of common stock available for future
 grant under the 2013 Plan.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 During the nine months ended September&amp;#xA0;30, 2014, we granted
 574,730 and 20,000 options to employees and consultants,
 respectively. During the nine months ended September&amp;#xA0;30, 2013,
 we granted 159,917 and 134,439 options to employees and
 consultants, respectively. The weighted average exercise price and
 the weighted-average grant-date fair value of options granted for
 the nine months ended September&amp;#xA0;30, 2014 was $11.91 per share
 and $8.73 per share, respectively. The fair value of the grants is
 being expensed over the vesting period of the options (four years)
 on a straight-line basis as the services are being provided.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 As of September&amp;#xA0;30, 2014, there was $6.1&amp;#xA0;million
 (includes compensation for options containing performance
 conditions) of unrecognized compensation cost related to the stock
 options granted under the 2006 Stock Incentive Plan and the 2013
 Plan. The compensation is expected to be recognized over the
 remaining requisite service period for options with a service
 condition, and upon the probability of achievement of performance
 conditions, as defined in the option agreement, for options with
 performance conditions. The weighted average remaining requisite
 service period was 3.1 years at September&amp;#xA0;30, 2014.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 In September 2013, certain performance-based stock option awards
 granted to two executives vested upon the closing of the
 Company&amp;#x2019;s IPO resulting in stock-based compensation expense
 of $3.6 million.&lt;/p&gt;


 &lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE730401--1410-Q0009_STD_273_20140930_0" decimals="2" id="id_4670348_DB100B7A-9F91-4F86-937E-D3A11E8F06D2_3_14" unitRef="iso4217_USD_per_shares">-1.46</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:FairValueDisclosuresTextBlock contextRef="eol_PE730401--1410-Q0009_STD_273_20140930_0" id="id_4670348_6618E040-4FBA-4EDA-ACBA-4CCD412E9453_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;5. FAIR VALUE MEASUREMENTS&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 As of September&amp;#xA0;30, 2014, and as of December&amp;#xA0;31, 2013,
 the carrying amounts of cash and cash equivalents, restricted cash,
 receivables, debt, accounts payable and accrued expenses
 approximated their estimated fair values because of the short-term
 nature of these financial instruments. All such measurements are
 Level 2 measurements in the fair value hierarchy. Included in cash
 and cash equivalents as of September&amp;#xA0;30, 2014, and
 December&amp;#xA0;31, 2013, are money market fund investments of
 $19.1&amp;#xA0;million and $44.7 million, and certificates of deposit
 of $0.5&amp;#xA0;million and $0.5 million, respectively.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 Fair value is defined as the exchange price that would be received
 for an asset or paid to transfer a liability (an exit price) in the
 principal or most advantageous market for the asset or liability in
 an orderly transaction between market participants on the
 measurement date. Valuation techniques used to measure fair value
 are performed in a manner to maximize the use of observable inputs
 and minimize the use of unobservable inputs. The accounting
 standard describes a fair value hierarchy based on three levels of
 inputs, of which the first two are considered observable and the
 last unobservable, that may be used to measure fair value, which
 are the following:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 &lt;i&gt;Level&amp;#xA0;1&lt;/i&gt;&amp;#x2014;Quoted prices in active markets that are
 accessible at the market date for identical unrestricted assets or
 liabilities.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 &lt;i&gt;Level&amp;#xA0;2&lt;/i&gt;&amp;#x2014;Inputs other than Level&amp;#xA0;1 that are
 observable, either directly or indirectly, such as quoted prices
 for similar assets or liabilities; quoted prices in markets that
 are not active; or other inputs for which all significant inputs
 are observable or can be corroborated by observable market data for
 substantially the full term of the assets or liabilities.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 &lt;i&gt;Level&amp;#xA0;3&lt;/i&gt;&amp;#x2014;Unobservable inputs that are supported by
 little or no market activity and that are significant to the fair
 value of the assets or liabilities.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 We value our marketable securities utilizing third party pricing
 services. The pricing services use many observable market inputs to
 determine value, including benchmark yields, reportable trades,
 broker/dealer quotes, issuer spreads, two-sided markets, benchmark
 securities, bids, offers, reference data, new issue data, monthly
 payment information and collateral performance. We validate the
 prices provided by our third party pricing services by
 understanding the models used, obtaining market values from other
 pricing sources, and confirming that those securities trade in
 active markets.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 There have been no changes to the valuation methods during the
 three and nine months ended September&amp;#xA0;30, 2014. We evaluate
 transfers between levels at the end of each reporting period. There
 were no transfers of assets or liabilities between Level 1 and
 Level&amp;#xA0;2 during the three months ended September&amp;#xA0;30, 2014.
 We had no short-term investments or long-term investments that were
 classified as Level 3 at any point during the nine months ended
 September&amp;#xA0;30, 2014 or during the year ended December&amp;#xA0;31,
 2013.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 The following table provides the assets carried at fair value
 measured on a recurring basis as of September&amp;#xA0;30, 2014, and
 December&amp;#xA0;31, 2013 (in thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="84%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="10" align="center"&gt;&lt;b&gt;Fair Value Measurements
 Using&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Carrying&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Value&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Quoted&amp;#xA0;Prices&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;in Active&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Markets for&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Identical&amp;#xA0;Assets&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;(Level 1)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Significant&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;other&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Observable&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Inputs&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;(Level 2)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Significant&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Unobservable&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Inputs&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;(Level 3)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 &lt;b&gt;&lt;u&gt;September&amp;#xA0;30, 2014&lt;/u&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Money market funds(1)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;19,625&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;19,625&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Certificates of deposit(2)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9,893&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9,893&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 U.S. government agency notes(2)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;17,259&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;17,259&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;46,777&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;19,625&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;27,152&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 &lt;b&gt;&lt;u&gt;December&amp;#xA0;31, 2013&lt;/u&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Money market funds(1)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;45,268&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;45,268&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Certificates of deposit(2)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,783&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,783&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 U.S. government agency notes(2)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;23,988&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;23,988&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;71,039&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;45,268&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;25,771&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 2pt; WHITE-SPACE: normal; BORDER-BOTTOM: rgb(0,0,0) 1px solid; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: medium/8pt 'Times New Roman'; MARGIN-TOP: 0pt; LETTER-SPACING: normal; WIDTH: 103px; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr&gt;
 &lt;td valign="top" width="4%" align="left"&gt;(1)&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;Money market funds are included
 within cash and cash equivalents and restricted cash in the
 accompanying Condensed Consolidated Balance Sheets.&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr&gt;
 &lt;td valign="top" width="4%" align="left"&gt;(2)&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;Certificates of deposit and U.S.
 government agency notes are included within short-term investments
 and long-term investments in the accompanying Condensed
 Consolidated Balance Sheets.&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;


 &lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
  <dei:DocumentFiscalPeriodFocus contextRef="eol_PE730401--1410-Q0009_STD_273_20140930_0" id="id_4670348_855E51D5-716C-4D8F-B578-A1152CA9D234_1_4">Q3</dei:DocumentFiscalPeriodFocus>
  <invest:InvestmentTextBlock contextRef="eol_PE730401--1410-Q0009_STD_273_20140930_0" id="id_4670348_8A5823DC-8DC5-48FF-9FA3-FBC6DF129DAF_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;4. SHORT-TERM AND LONG-TERM INVESTMENTS&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 Short-term and long-term investments represent holdings of
 available-for-sale marketable securities in accordance with our
 investment policy and cash management strategy. Short-term
 investments mature within 12 months from the balance sheet date and
 long-term marketable securities represent investments with maturity
 dates greater than one year from the balance sheet date. At the
 time that the maturity dates of these investments become one year
 or less, the securities are reclassified as short-term investments.
 Our investments in marketable securities are recorded at fair
 value, with any unrealized gains and losses, net of taxes, reported
 as a component of stockholders&amp;#x2019; equity until realized or
 until a determination is made that an other-than-temporary decline
 in market value has occurred. The cost of marketable securities
 sold is determined based on the specific identification method and
 any realized gains or losses on the sale of investments are
 reflected as a component of interest income (expense), net.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 The following is a summary of marketable securities (included in
 short and long-term investments in the Condensed Consolidated
 Balance Sheets) as of September&amp;#xA0;30, 2014 and December&amp;#xA0;31,
 2013 (in thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="87%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Amortized&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Cost&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Gross&amp;#xA0;Unrealized&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Gains&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Gross&amp;#xA0;Unrealized&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Losses&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Fair&amp;#xA0;Value&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 &lt;b&gt;&lt;u&gt;September&amp;#xA0;30, 2014&lt;/u&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Certificates of deposit&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9,900&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(7&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9,893&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 U.S. government agency notes&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;17,255&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;17,259&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;27,155&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(7&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;27,152&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 &lt;b&gt;&lt;u&gt;December&amp;#xA0;31, 2013&lt;/u&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Certificates of deposit&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,784&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(1&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,783&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 U.S. government agency notes&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;23,987&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(2&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;23,988&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;25,771&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(3&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;25,771&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 The contractual maturities of the marketable securities as of
 September&amp;#xA0;30, 2014 are all due within one year. We had zero
 and $10,000 of realized gains on our short-term investments for the
 three and nine months ended September&amp;#xA0;30, 2014, respectively.
 We had no realized gains or losses on our short-term investments
 for the three and nine months ended September&amp;#xA0;30, 2013. Our
 certificates of deposit are each under $250,000 and are subject to
 insurance by the Federal Deposit Insurance Corporation. There were
 no other-than-temporary impairments recognized for the three and
 nine months ended September&amp;#xA0;30, 2014 and 2013.&lt;/p&gt;


 &lt;/div&gt;</invest:InvestmentTextBlock>
  <us-gaap:RevenueFromGrants contextRef="eol_PE730401--1410-Q0009_STD_273_20140930_0" decimals="-3" id="id_4670348_D9FA225F-6D99-4C5D-B451-F03E65B46305_3_0" unitRef="iso4217_USD">418000</us-gaap:RevenueFromGrants>
  <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="eol_PE730401--1410-Q0009_STD_273_20140930_0" decimals="-3" id="id_4670348_DBE2D5B3-EBC6-464B-B7BC-30D3DADAFE8D_3_2" unitRef="iso4217_USD">-1034000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
  <us-gaap:RepaymentsOfLongTermCapitalLeaseObligations contextRef="eol_PE730401--1410-Q0009_STD_273_20140930_0" decimals="-3" id="id_4670348_B3537E10-5158-4A83-93D5-A92106642A08_1_26" unitRef="iso4217_USD">38000</us-gaap:RepaymentsOfLongTermCapitalLeaseObligations>
  <us-gaap:RepaymentsOfLongTermLinesOfCredit contextRef="eol_PE730401--1410-Q0009_STD_273_20140930_0" decimals="-3" id="id_4670348_B3537E10-5158-4A83-93D5-A92106642A08_1_28" unitRef="iso4217_USD">806000</us-gaap:RepaymentsOfLongTermLinesOfCredit>
  <us-gaap:PaymentsToAcquireShortTermInvestments contextRef="eol_PE730401--1410-Q0009_STD_273_20140930_0" decimals="-3" id="id_4670348_B3537E10-5158-4A83-93D5-A92106642A08_1_17" unitRef="iso4217_USD">31889000</us-gaap:PaymentsToAcquireShortTermInvestments>
  <us-gaap:MarketableSecuritiesRealizedGainLoss contextRef="eol_PE730401--1410-Q0009_STD_273_20140930_0" decimals="0" id="id_4670348_DAE93F34-720D-43E9-9828-5829AE57083D_1_1" unitRef="iso4217_USD">10000</us-gaap:MarketableSecuritiesRealizedGainLoss>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="eol_PE730401--1410-Q0009_STD_273_20140930_0" decimals="-3" id="id_4670348_B3537E10-5158-4A83-93D5-A92106642A08_1_9" unitRef="iso4217_USD">-731000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE730401--1410-Q0009_STD_273_20140930_0" decimals="-3" id="id_4670348_DB100B7A-9F91-4F86-937E-D3A11E8F06D2_3_5" unitRef="iso4217_USD">-24328000</us-gaap:OperatingIncomeLoss>
  <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="eol_PE730401--1410-Q0009_STD_273_20140930_0" decimals="-3" id="id_4670348_DB100B7A-9F91-4F86-937E-D3A11E8F06D2_3_7" unitRef="iso4217_USD">-197000</us-gaap:InterestIncomeExpenseNonoperatingNet>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="eol_PE730401--1410-Q0009_STD_273_20140930_0" decimals="-3" id="id_4670348_DBE2D5B3-EBC6-464B-B7BC-30D3DADAFE8D_3_4" unitRef="iso4217_USD">-25080000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:NonoperatingIncomeExpense contextRef="eol_PE730401--1410-Q0009_STD_273_20140930_0" decimals="-3" id="id_4670348_DB100B7A-9F91-4F86-937E-D3A11E8F06D2_3_9" unitRef="iso4217_USD">285000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:PaymentsForProceedsFromOtherInvestingActivities contextRef="eol_PE730401--1410-Q0009_STD_273_20140930_0" decimals="-3" id="id_4670348_B3537E10-5158-4A83-93D5-A92106642A08_1_19" unitRef="iso4217_USD">184000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="eol_PE730401--1410-Q0009_STD_273_20140930_0" decimals="-3" id="id_4670348_DB100B7A-9F91-4F86-937E-D3A11E8F06D2_3_8" unitRef="iso4217_USD">482000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:Revenues contextRef="eol_PE730401--1410-Q0009_STD_273_20140930_0" decimals="-3" id="id_4670348_DB100B7A-9F91-4F86-937E-D3A11E8F06D2_3_0" unitRef="iso4217_USD">7389000</us-gaap:Revenues>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="eol_PE730401--1410-Q0009_STD_273_20140930_0" decimals="-3" id="id_4670348_B3537E10-5158-4A83-93D5-A92106642A08_1_14" unitRef="iso4217_USD">2588000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:OtherNoncashIncomeExpense contextRef="eol_PE730401--1410-Q0009_STD_273_20140930_0" decimals="-3" id="id_4670348_B3537E10-5158-4A83-93D5-A92106642A08_1_6" unitRef="iso4217_USD">-55000</us-gaap:OtherNoncashIncomeExpense>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="eol_PE730401--1410-Q0009_STD_273_20140930_0" decimals="-3" id="id_4670348_DB100B7A-9F91-4F86-937E-D3A11E8F06D2_3_12" unitRef="iso4217_USD">-24043000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:NetIncomeLoss contextRef="eol_PE730401--1410-Q0009_STD_273_20140930_0" decimals="-3" id="id_4670348_DB100B7A-9F91-4F86-937E-D3A11E8F06D2_3_10" unitRef="iso4217_USD">-24043000</us-gaap:NetIncomeLoss>
  <us-gaap:InterestPaid contextRef="eol_PE730401--1410-Q0009_STD_273_20140930_0" decimals="-3" id="id_4670348_B3537E10-5158-4A83-93D5-A92106642A08_1_40" unitRef="iso4217_USD">486000</us-gaap:InterestPaid>
  <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="eol_PE730401--1410-Q0009_STD_273_20140930_0" decimals="-3" id="id_4670348_B3537E10-5158-4A83-93D5-A92106642A08_1_8" unitRef="iso4217_USD">1172000</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="eol_PE730401--1410-Q0009_STD_273_20140930_0" decimals="-3" id="id_4670348_DBE2D5B3-EBC6-464B-B7BC-30D3DADAFE8D_3_3" unitRef="iso4217_USD">-3000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
  <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="eol_PE730401--1410-Q0009_STD_273_20140930_0" decimals="INF" id="id_4670348_CE23F58B-9271-448F-A639-4E08DC56FDE9_1_3" unitRef="iso4217_USD">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
  <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="eol_PE730401--1410-Q0009_STD_273_20140930_0" decimals="-3" id="id_4670348_B3537E10-5158-4A83-93D5-A92106642A08_1_35" unitRef="iso4217_USD">21000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
  <us-gaap:DepreciationDepletionAndAmortization contextRef="eol_PE730401--1410-Q0009_STD_273_20140930_0" decimals="-3" id="id_4670348_B3537E10-5158-4A83-93D5-A92106642A08_1_3" unitRef="iso4217_USD">1314000</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="eol_PE730401--1410-Q0009_STD_273_20140930_0" decimals="-3" id="id_4670348_B3537E10-5158-4A83-93D5-A92106642A08_1_11" unitRef="iso4217_USD">-1665000</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:OperatingExpenses contextRef="eol_PE730401--1410-Q0009_STD_273_20140930_0" decimals="-3" id="id_4670348_DB100B7A-9F91-4F86-937E-D3A11E8F06D2_3_4" unitRef="iso4217_USD">31717000</us-gaap:OperatingExpenses>
  <us-gaap:ProceedsFromSaleOfShortTermInvestments contextRef="eol_PE730401--1410-Q0009_STD_273_20140930_0" decimals="-3" id="id_4670348_B3537E10-5158-4A83-93D5-A92106642A08_1_15" unitRef="iso4217_USD">11759000</us-gaap:ProceedsFromSaleOfShortTermInvestments>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE730401--1410-Q0009_STD_273_20140930_0" decimals="-3" id="id_4670348_DB100B7A-9F91-4F86-937E-D3A11E8F06D2_3_2" unitRef="iso4217_USD">20855000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:EffectOfExchangeRateOnCash contextRef="eol_PE730401--1410-Q0009_STD_273_20140930_0" decimals="-3" id="id_4670348_B3537E10-5158-4A83-93D5-A92106642A08_1_30" unitRef="iso4217_USD">-562000</us-gaap:EffectOfExchangeRateOnCash>
  <us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations contextRef="eol_PE730401--1410-Q0009_STD_273_20140930_0" decimals="INF" id="id_4670348_F5546513-4A39-4E4B-9C34-956EA3533939_1_0" unitRef="iso4217_USD">0</us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations>
  <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments contextRef="eol_PE730401--1410-Q0009_STD_273_20140930_0" decimals="-3" id="id_4670348_B3537E10-5158-4A83-93D5-A92106642A08_1_16" unitRef="iso4217_USD">18455000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="eol_PE730401--1410-Q0009_STD_273_20140930_0" decimals="-3" id="id_4670348_B3537E10-5158-4A83-93D5-A92106642A08_1_31" unitRef="iso4217_USD">-27852000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="eol_PE730401--1410-Q0009_STD_273_20140930_0" decimals="-3" id="id_4670348_B3537E10-5158-4A83-93D5-A92106642A08_1_29" unitRef="iso4217_USD">-875000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="eol_PE730401--1410-Q0009_STD_273_20140930_0" decimals="-3" id="id_4670348_B3537E10-5158-4A83-93D5-A92106642A08_1_25" unitRef="iso4217_USD">234000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations contextRef="eol_PE730401--1410-Q0009_STD_273_20140930_0" decimals="INF" id="id_4670348_F5546513-4A39-4E4B-9C34-956EA3533939_1_1" unitRef="iso4217_USD">0</us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="eol_PE730401--1410-Q0009_STD_273_20140930_0" decimals="-3" id="id_4670348_B3537E10-5158-4A83-93D5-A92106642A08_1_20" unitRef="iso4217_USD">-4447000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE730401--1410-Q0009_STD_273_20140930_0" decimals="-3" id="id_4670348_DB100B7A-9F91-4F86-937E-D3A11E8F06D2_3_3" unitRef="iso4217_USD">10862000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="eol_PE730401--1410-Q0009_STD_273_20140930_0" decimals="-3" id="id_4670348_B3537E10-5158-4A83-93D5-A92106642A08_1_10" unitRef="iso4217_USD">767000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:ProceedsFromIssuanceInitialPublicOffering contextRef="eol_PE730401--1410-Q0009_STD_273_20140930_0" decimals="-3" id="id_4670348_B3537E10-5158-4A83-93D5-A92106642A08_1_24" unitRef="iso4217_USD">-265000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE730401--1410-Q0009_STD_273_20140930_0" decimals="-3" id="id_4670348_B3537E10-5158-4A83-93D5-A92106642A08_1_4" unitRef="iso4217_USD">2045000</us-gaap:ShareBasedCompensation>
  <us-gaap:MarketableSecuritiesRealizedGainLossOtherThanTemporaryImpairmentsAmount contextRef="eol_PE730401--1410-Q0009_STD_273_20140930_0" decimals="INF" id="id_4670348_DAE93F34-720D-43E9-9828-5829AE57083D_1_2" unitRef="iso4217_USD">0</us-gaap:MarketableSecuritiesRealizedGainLossOtherThanTemporaryImpairmentsAmount>
  <bind:SignificantAccountingPoliciesPolicyTextBlock contextRef="eol_PE730401--1410-Q0009_STD_273_20140930_0" id="id_4670348_58EBE9FB-9F5E-4D9E-9AB8-700F43696721_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 &lt;b&gt;Summary of Significant Accounting Policies&lt;/b&gt;&amp;#x2014;There have
 been no material changes to the significant accounting policies
 previously disclosed in our Annual Report on Form 10-K for the year
 ended December&amp;#xA0;31, 2013.&lt;/p&gt;
 &lt;/div&gt;</bind:SignificantAccountingPoliciesPolicyTextBlock>
  <bind:ShortTermMarketableSecurityMaturityPeriod contextRef="eol_PE730401--1410-Q0009_STD_273_20140930_0" id="id_4670348_DAE93F34-720D-43E9-9828-5829AE57083D_1_0">P1Y</bind:ShortTermMarketableSecurityMaturityPeriod>
  <bind:LineOfCreditFacilityBasisSpreadOnPrimeRate contextRef="eol_PE730401--1410-Q0009_STD_273_20140930_0" decimals="4" id="id_4670348_F42EDA83-2E23-4302-82F9-A31E62F850C3_1_1" unitRef="pure">0.0325</bind:LineOfCreditFacilityBasisSpreadOnPrimeRate>
  <bind:DevelopmentStageRisksLiquidityAndGoingConcernPolicyTextBlock contextRef="eol_PE730401--1410-Q0009_STD_273_20140930_0" id="id_4670348_E623EE86-525E-4321-8E30-8A3FDE9C4971_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;

 On August&amp;#xA0;27, 2014, the Financial Accounting Standards Board
 (&amp;#x201C;FASB&amp;#x201D;) issued ASU 2014-15,&amp;#xA0;&lt;i style="FONT-SIZE: 13px; FONT-FAMILY: 'Times New Roman'; FONT-VARIANT: normal; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); LETTER-SPACING: normal; LINE-HEIGHT: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;Disclosure
 of Uncertainties about an Entity&amp;#x2019;s Ability to Continue as a
 Going Concern&lt;/i&gt;&amp;#xA0;(&amp;#x201C;ASU
 2014-15&amp;#x201D;), which provides guidance on determining when and
 how to disclose going-concern uncertainties in the financial
 statements. The new standard requires management to perform interim
 and annual assessments of an entity&amp;#x2019;s ability to continue as
 a going concern within one year of the date the financial
 statements are issued. An entity must provide certain disclosures
 if &amp;#x201C;conditions or events raise substantial doubt about the
 entity&amp;#x2019;s ability to continue as a going concern.&amp;#x201D; ASU
 2014-15 is effective for us on January&amp;#xA0;1, 2017, with early
 adoption permitted. We are currently assessing the potential impact
 of the adoption of ASU 2014-15 on our condensed consolidated
 financial statements.&lt;/p&gt;
 &lt;/div&gt;</bind:DevelopmentStageRisksLiquidityAndGoingConcernPolicyTextBlock>
  <bind:ScheduleOfNetRevenuesTableTextBlock contextRef="eol_PE730401--1410-Q0009_STD_273_20140930_0" id="id_4670348_04C73A5E-17D9-4B2E-89E3-8DEA7AD407C0_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 Our revenue for the periods presented consists of the following (in
 thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="72%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"&gt;
 &lt;b&gt;Three&amp;#xA0;Months&amp;#xA0;Ended&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;September 30,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;Nine&amp;#xA0;Months&amp;#xA0;Ended&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;September 30,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Government grants&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;151&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;418&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;516&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Research and development agreements&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,365&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,415&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,971&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,315&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,365&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,566&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7,389&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,831&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;br class="Apple-interchange-newline" /&gt;

 &lt;/div&gt;</bind:ScheduleOfNetRevenuesTableTextBlock>
  <bind:ProceedsFromGrants contextRef="eol_PE730401--1410-Q0009_STD_273_20140930_0" decimals="-5" id="id_4670348_5F0954C3-DC3B-4A43-A300-67705006E574_1_0" unitRef="iso4217_RUB">22300000</bind:ProceedsFromGrants>
  <bind:ProceedsFromGrants contextRef="eol_PE730401--1410-Q0009_STD_273_20140930_0" decimals="-5" id="id_4670348_5F0954C3-DC3B-4A43-A300-67705006E574_3_0" unitRef="iso4217_USD">600000</bind:ProceedsFromGrants>
  <bind:DebtInstrumentNumberOfInstallments contextRef="eol_PE730401--1410-Q0009_STD_273_20140930_0" decimals="INF" id="id_4670348_F42EDA83-2E23-4302-82F9-A31E62F850C3_1_3" unitRef="Installment">30</bind:DebtInstrumentNumberOfInstallments>
  <bind:ResearchAndDevelopmentCollaborationAgreementRevenue contextRef="eol_PE730401--1410-Q0009_STD_273_20140930_0" decimals="-3" id="id_4670348_D9FA225F-6D99-4C5D-B451-F03E65B46305_3_1" unitRef="iso4217_USD">6971000</bind:ResearchAndDevelopmentCollaborationAgreementRevenue>
  <bind:RevenueRecognitionDisclosureTextBlock contextRef="eol_PE730401--1410-Q0009_STD_273_20140930_0" id="id_4670348_D8051A65-CC78-499B-B55A-5AFFD36890FB_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;3. REVENUE&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 Our revenue for the periods presented consists of the following (in
 thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="72%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"&gt;
 &lt;b&gt;Three&amp;#xA0;Months&amp;#xA0;Ended&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;September 30,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;Nine&amp;#xA0;Months&amp;#xA0;Ended&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;September 30,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Government grants&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;151&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;418&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;516&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Research and development agreements&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,365&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,415&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,971&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,315&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,365&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,566&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7,389&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,831&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;Government Grants&lt;/b&gt;&amp;#x2014;Government grants consist primarily
 of research grants from the Ministry for Industry and Trade of the
 Russian Federation (&amp;#x201C;MPT Grant&amp;#x201D;) awarded in October
 2012. Advance funding under the contract of 22.3&amp;#xA0;million
 Rubles (RUB) ($0.6 million) and 19.9&amp;#xA0;million RUB ($0.6
 million) was received during the nine months ended
 September&amp;#xA0;30, 2014 and 2013, respectively. Revenue recognized
 for this contract for the three and nine months ended
 September&amp;#xA0;30, 2014, was zero and $0.4 million, respectively.
 Revenue recognized for this contract for the three and nine months
 ended September&amp;#xA0;30, 2013, was $0.2 million and $0.5 million,
 respectively. Cash received from the MPT Grant that exceeds revenue
 recognized has been recorded in deferred revenue.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;Research and Development and Collaboration
 Agreements&lt;/b&gt;&amp;#x2014;Revenue recognized for research and
 development agreements in the three and nine months ended
 September&amp;#xA0;30, 2014 and 2013 relate principally to our 2013
 agreements with large pharmaceutical and biotechnology companies.
 Under these agreements, we perform research and/or studies to
 assess the feasibility of developing Accurins incorporating
 therapeutic payloads from such pharmaceutical and biotechnology
 companies&amp;#x2019; proprietary product portfolios and provide the
 resulting data from such work to the pharmaceutical and
 biotechnology companies in exchange for reimbursement for research
 and development services and upfront fees for which revenue
 recognition was initially deferred and is being recognized over the
 performance period.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;F. Hoffmann-La Roche Ltd.&lt;/b&gt;&amp;#x2014;In June 2014, we entered
 into a research agreement with F. Hoffmann-La Roche Ltd. and
 Hoffmann-La Roche Inc., or Roche, to discover novel nanomedicines
 using Accurins for the treatment of diseases in therapeutic areas
 outside of oncology. The research agreement focuses on combining
 BIND&amp;#x2019;s Accurin technology with Roche&amp;#x2019;s proprietary
 therapeutic payloads and targeting ligands. Under the agreement,
 Roche paid us an immaterial, non-refundable upfront fee and,
 additionally, will compensate us for our research and development
 services up to a specified amount. The upfront fee, which was
 received by us in July 2014, will be creditable against any such
 fee negotiated in a future Roche agreement, if any. Therefore, we
 will not recognize revenue related to the upfront fee during the
 term of the research agreement. During the three and nine months
 ended September&amp;#xA0;30, 2014, we recognized revenue of $0.3
 million for reimbursed research and development activities related
 to the Roche research agreement.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;AstraZeneca AB&lt;/b&gt;&amp;#x2014;In April 2013, we entered into a
 license agreement with AstraZeneca. Under the agreement, we granted
 to AstraZeneca a worldwide license to research, develop,
 manufacture and commercialize Accurins incorporating a specified
 AstraZeneca product candidate for any therapeutic use in humans or
 animals. This license is exclusive with respect to our intellectual
 property rights that arise under this agreement or the feasibility
 study that preceded it, and non-exclusive with respect to all of
 our other intellectual property rights. We and AstraZeneca are each
 responsible for using commercially reasonable efforts to develop
 licensed products under a development plan that extends a
 previously completed feasibility study we conducted for
 AstraZeneca. AstraZeneca is required to pay for all of our
 development costs. AstraZeneca is also solely responsible for, and
 must use commercially reasonable efforts in, obtaining all
 regulatory approvals for licensed products.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 Under the agreement, we received an upfront payment of $4.0 million
 and have the potential to receive contingent payments totaling up
 to $193 million in the aggregate upon achievement by AstraZeneca of
 specified clinical, regulatory and commercial events. We will also
 receive tiered royalties in the low-single digit to the low-double
 digit percentages of aggregate worldwide net sales of licensed
 product, if any. We will receive royalties on a country-by-country
 and licensed product-by-licensed product basis generally until the
 AstraZeneca patents and any regulatory exclusivity relating to such
 licensed product expire.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 We determined that the deliverables under the agreement include the
 license, the research and development services and participation in
 the Joint Steering Committee (&amp;#x201C;JSC&amp;#x201D;). The JSC
 deliverable ends at the same time as the research and development
 services. Our obligations related to the research and development
 services are to use commercially reasonable efforts to perform the
 research as set forth in the design/preclinical collaboration plan.
 We also determined that, pursuant to the accounting guidance
 governing revenue recognition on multiple element arrangements, the
 license and undelivered research and development services and
 participation in the JSC do not have standalone value due to the
 specialized nature of the research services to be provided by us.
 In addition, while AstraZeneca has the ability to grant
 sublicenses, it cannot sublicense all or substantially all of its
 rights under the agreement. The uniqueness of the Company&amp;#x2019;s
 research services and the limited sublicense right are indicators
 that standalone value is not present in the arrangement. Therefore
 the deliverables are not separable and, accordingly, the license
 and undelivered research and development and JSC services are being
 treated as a single unit of accounting. When multiple deliverables
 are accounted for as a single unit of accounting, we base our
 revenue recognition model on the final deliverable, since multiple
 deliverables are accounted for as a single unit of accounting.
 Under the agreement, the last deliverable to be completed is the
 research and development services and participation in the JSC
 which are expected to be completed in 2015. We are utilizing a
 proportional performance model to recognize revenue related to the
 upfront payment and our other research and development services
 (both our internal effort as well as external costs). During the
 three months ended September&amp;#xA0;30, 2014 and 2013, we recognized
 revenue of $2.8 million and $1.3 million, respectively, and during
 the nine months ended September&amp;#xA0;30, 2014 and 2013, we
 recognized revenue of $5.5 million and $1.9 million, respectively,
 related to the AstraZeneca license agreement.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;Pfizer&amp;#xA0;Inc.&lt;/b&gt;&amp;#x2014;In March 2013, we entered into a
 research, option and license agreement with Pfizer Inc. pursuant to
 which we granted to Pfizer two options to obtain an exclusive
 worldwide license to use, develop, manufacture and commercialize
 Accurins incorporating specified Pfizer drug candidates, for the
 treatment, prevention and/or diagnosis of any disease or medical
 condition in humans, except that the licensed rights exclude some
 vaccine products and products for the treatment of brain cancer.
 Pfizer may exercise either one or both of its options to acquire
 the exclusive license for the specified drug candidate until
 September 2015, subject to certain adjustments, by paying us a
 specified option exercise fee. If Pfizer exercises any option, it
 will be solely responsible for all further development and
 commercialization activities with respect to the licensed products
 covered by the option, and Pfizer is also solely responsible for
 obtaining all regulatory approvals for the applicable licensed
 products and conducting all communications with regulatory
 authorities.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 Under the agreement, we received an upfront payment of $4.0 million
 and have the potential to receive contingent payments totaling up
 to $89.5 million in the aggregate under each option upon exercise
 of the option and achievement by Pfizer of specified development
 and regulatory events plus additional contingent payments totaling
 up to $110 million in the aggregate under each option upon
 achievement by Pfizer of specified commercial events. We will also
 receive royalties in the low-single digit to the high-single digit
 percentages of aggregate worldwide net sales of each licensed
 product, if any. We will receive royalties on a country-by-country
 and licensed product-by-licensed product basis generally until the
 expiration of the Pfizer patents covering such licensed
 product.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 Our deliverables under the agreement include the research and
 development services and participation on a Joint Research
 Committee (&amp;#x201C;JRC&amp;#x201D;). The JRC deliverable ends at the same
 time as the research and development services. Our obligations
 related to the research and development services are to use
 commercially reasonable efforts to perform the research as set
 forth in the design/preclinical collaboration plan. We determined
 that the JRC does not have standalone value apart from the research
 and development services, and we considered these deliverables a
 single unit of accounting. We concluded that the Pfizer options are
 not deliverables of the agreement because they are substantive
 options and are not priced at a significant and incremental
 discount. The performance period is the expected period over which
 the services of the combined unit are performed, which we expect
 will span through 2015. We are utilizing a proportional performance
 model to recognize both the upfront payment and our other research
 and development services (both our internal effort as well as
 external costs). During the three months ended September&amp;#xA0;30,
 2014 and 2013, we recognized revenue of $0.3 million and $1.4
 million, respectively, and during the nine months ended
 September&amp;#xA0;30, 2014 and 2013, we recognized revenue of $0.4
 million and $2.1 million, respectively, related to the Pfizer
 research, option and license agreement.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;Amgen,&amp;#xA0;Inc.&lt;/b&gt;&amp;#x2014;In January 2013, we entered into a
 license agreement with Amgen, Inc. (&amp;#x201C;Amgen&amp;#x201D;), pursuant
 to which we granted to Amgen an option to obtain an exclusive
 worldwide license to develop, manufacture and commercialize an
 Accurin incorporating a specified Amgen drug candidate for all uses
 except for some vaccine applications (&amp;#x201C;Amgen Option&amp;#x201D;).
 Under the agreement, we received an upfront payment of $5.0 million
 as well as potential development and regulatory milestone payments
 contingent upon Amgen exercising its option.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 Our deliverables under the agreement included conducting the
 research and development program and participation on a JRC. The
 JRC deliverable ended at the same time as the research and
 development services. Our obligations related to the research and
 development services were to use commercially reasonable efforts to
 perform the research as set forth in the design/preclinical
 collaboration plan. Having determined that the JRC did not have
 standalone value apart from the research and development program,
 we considered these deliverables as a single unit of accounting. We
 concluded that the Amgen Option was not a deliverable of the
 agreement because it was a substantive option and was not priced at
 a significant and incremental discount. The performance period was
 the expected period over which the services of the combined unit
 were performed, which we expected would span through the middle of
 2014. The upfront payment was being recognized over the performance
 period on a proportional performance basis.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 In December 2013, we and Amgen amended the license agreement to
 extend the period during which Amgen may exercise its option by
 nine months, to July 2014. In June 2014, Amgen notified us that it
 would not exercise its option; therefore, we had no further
 performance obligations to Amgen. As a result, we recognized the
 remaining portion of the upfront license fee of $0.8 million as
 revenue during the three months ended June&amp;#xA0;30, 2014. In June
 2014, we also notified Amgen that we would not exercise our option
 to develop an Accurin incorporating the Amgen therapeutic
 payload.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 The change in accounting estimate related to the upfront payment
 proportional performance calculation resulted in a reduction in net
 loss of $0.05 in basic and diluted loss per share for the three
 months ended June&amp;#xA0;30, 2014. During the three months ended
 September&amp;#xA0;30, 2014 and 2013, we recognized revenue of zero and
 $1.6 million, respectively, and during the nine months ended
 September&amp;#xA0;30, 2014 and 2013, we recognized revenue of $0.8
 million and $3.9 million, respectively, related to the Amgen
 license agreement.&lt;/p&gt;


 &lt;/div&gt;</bind:RevenueRecognitionDisclosureTextBlock>
  <bind:LeaseExpirationMonthAndYear contextRef="eol_PE730401--1410-Q0009_STD_273_20140930_0" id="id_4670348_EFC1457D-834B-4926-ACFF-340014BB0C27_1_0">2017-04</bind:LeaseExpirationMonthAndYear>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE730401--1410-Q0009_STD_273_20140930_0_1268687x1273442" decimals="INF" id="id_4670348_F63211FA-4135-41EF-B531-8D9E7B2CC12D_2001_1" unitRef="shares">74412</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE730401--1410-Q0009_STD_273_20140930_0_1268687x1275629" decimals="INF" id="id_4670348_F63211FA-4135-41EF-B531-8D9E7B2CC12D_3001_0" unitRef="shares">2593012</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:LineOfCreditFacilityInterestRateDuringPeriod contextRef="eol_PE730401--1410-Q0009_STD_273_20140930_0_1269523x1277596" decimals="INF" id="id_4670348_F42EDA83-2E23-4302-82F9-A31E62F850C3_1001_2" unitRef="pure">0.1025</us-gaap:LineOfCreditFacilityInterestRateDuringPeriod>
  <us-gaap:DeferredRevenueRevenueRecognized contextRef="eol_PE730401--1410-Q0009_STD_273_20140930_0_1272072x1314996" decimals="-5" id="id_4670348_ED12A3E8-4383-4C29-8FDB-2DF3A8428EF4_1004_2" unitRef="iso4217_USD">800000</us-gaap:DeferredRevenueRevenueRecognized>
  <us-gaap:DeferredRevenueRevenueRecognized contextRef="eol_PE730401--1410-Q0009_STD_273_20140930_0_1272072x1324174" decimals="-5" id="id_4670348_8BD5C7E7-CB70-43EB-9E85-79AD257C419F_1002_0" unitRef="iso4217_USD">300000</us-gaap:DeferredRevenueRevenueRecognized>
  <us-gaap:DeferredRevenueRevenueRecognized contextRef="eol_PE730401--1410-Q0009_STD_273_20140930_0_1272072x1367107" decimals="-5" id="id_4670348_52F36303-2E76-4586-A3E2-681220880A58_1003_0" unitRef="iso4217_USD">5500000</us-gaap:DeferredRevenueRevenueRecognized>
  <us-gaap:DeferredRevenueRevenueRecognized contextRef="eol_PE730401--1410-Q0009_STD_273_20140930_0_1272072x1545620" decimals="-5" id="id_4670348_65524187-74EE-48E7-A63D-F61D3DA4864A_1003_0" unitRef="iso4217_USD">400000</us-gaap:DeferredRevenueRevenueRecognized>
  <us-gaap:RevenueFromGrants contextRef="eol_PE730401--1410-Q0009_STD_273_20140930_0_1272072x1592869_1273333x1278099" decimals="-5" id="id_4670348_5F0954C3-DC3B-4A43-A300-67705006E574_1003_1" unitRef="iso4217_USD">400000</us-gaap:RevenueFromGrants>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="eol_PE730401--1410-Q0009_STD_273_20140930_0_1273383x1448784" decimals="INF" id="id_4670348_727810A8-253A-474F-8A13-6E9F9637AAF8_1001_3" unitRef="shares">20000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="eol_PE730401--1410-Q0009_STD_273_20140930_0_1273383x1502643" decimals="INF" id="id_4670348_727810A8-253A-474F-8A13-6E9F9637AAF8_2001_2" unitRef="shares">574730</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE730401--1410-Q0009_STD_273_20140930_0_1274159x1269133" decimals="-3" id="id_4670348_6D77B0DA-1186-42D9-8241-0E457372E26C_1003_1" unitRef="iso4217_USD">1062000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE730401--1410-Q0009_STD_273_20140930_0_1274159x1269570" decimals="-3" id="id_4670348_6D77B0DA-1186-42D9-8241-0E457372E26C_2003_0" unitRef="iso4217_USD">983000</us-gaap:ShareBasedCompensation>
  <bind:ReceivedUpfrontCashPayment contextRef="eol_PE730401--1410-Q0009_STD_30_20130430_0_1272072x1367107" decimals="-5" id="id_4670348_B6684E62-1D77-47C3-96B1-CA830D930BF9_1001_0" unitRef="iso4217_USD">4000000</bind:ReceivedUpfrontCashPayment>
  <us-gaap:RepaymentsOfSecuredDebt contextRef="eol_PE730401--1410-Q0009_STD_30_20130630_0_1269523x1277596" decimals="-5" id="id_4670348_CE23F58B-9271-448F-A639-4E08DC56FDE9_1002_2" unitRef="iso4217_USD">2300000</us-gaap:RepaymentsOfSecuredDebt>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE730401--1410-Q0009_STD_30_20130930_0" decimals="-5" id="id_4670348_B699A304-1EC6-47AC-B201-517C02799140_1_1" unitRef="iso4217_USD">3600000</us-gaap:AllocatedShareBasedCompensationExpense>
  <bind:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNumberOfExecutives contextRef="eol_PE730401--1410-Q0009_STD_30_20130930_0" decimals="INF" id="id_4670348_B699A304-1EC6-47AC-B201-517C02799140_1_0" unitRef="Executives">2</bind:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNumberOfExecutives>
  <bind:ReceivedUpfrontCashPayment contextRef="eol_PE730401--1410-Q0009_STD_31_20130131_0_1272072x1314996" decimals="-5" id="id_4670348_F2510990-8E36-4F3A-8FFD-79121E0A62CE_1001_0" unitRef="iso4217_USD">5000000</bind:ReceivedUpfrontCashPayment>
  <bind:MaximumAggregateCommonStockOfferingPrice contextRef="eol_PE730401--1410-Q0009_STD_31_20141031_0_1271378x1273350" decimals="INF" id="id_4670348_B287BFF6-87D9-45DC-9F5F-F362F68A2BB1_1001_0" unitRef="iso4217_USD">40000000</bind:MaximumAggregateCommonStockOfferingPrice>
  <bind:ReceivedUpfrontCashPayment contextRef="eol_PE730401--1410-Q0009_STD_31_20130331_0_1272072x1545620" decimals="-5" id="id_4670348_E4EDFA55-B8D6-45F2-ABD4-0C5B4B0E9BA2_1001_0" unitRef="iso4217_USD">4000000</bind:ReceivedUpfrontCashPayment>
  <bind:AgreementExpirationPeriodMonthAndYear contextRef="eol_PE730401--1410-Q0009_STD_31_20130331_0_1272072x1545620" id="id_4670348_136AC317-25AE-4668-B064-426AB60ACFB0_1001_1">2015-09</bind:AgreementExpirationPeriodMonthAndYear>
  <bind:NumberOfOptionsToObtainLicenseUnderAgreement contextRef="eol_PE730401--1410-Q0009_STD_31_20130331_0_1272072x1545620" decimals="INF" id="id_4670348_136AC317-25AE-4668-B064-426AB60ACFB0_1001_0" unitRef="Option">2</bind:NumberOfOptionsToObtainLicenseUnderAgreement>
  <bind:LicenseAgreementOptionExercisePeriod contextRef="eol_PE730401--1410-Q0009_STD_31_20131231_0_1272072x1314996" id="id_4670348_99E09915-2A4F-4E24-8C38-40DEF4D84F97_1001_0">P9M</bind:LicenseAgreementOptionExercisePeriod>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="eol_PE730401--1410-Q0009_STD_92_20130930_0" decimals="0" id="id_4670348_DB100B7A-9F91-4F86-937E-D3A11E8F06D2_2_16" unitRef="shares">3391239</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE730401--1410-Q0009_STD_92_20130930_0" decimals="2" id="id_4670348_DB100B7A-9F91-4F86-937E-D3A11E8F06D2_2_14" unitRef="iso4217_USD_per_shares">-2.46</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:RevenueFromGrants contextRef="eol_PE730401--1410-Q0009_STD_92_20130930_0" decimals="-3" id="id_4670348_D9FA225F-6D99-4C5D-B451-F03E65B46305_2_0" unitRef="iso4217_USD">151000</us-gaap:RevenueFromGrants>
  <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="eol_PE730401--1410-Q0009_STD_92_20130930_0" decimals="-3" id="id_4670348_DBE2D5B3-EBC6-464B-B7BC-30D3DADAFE8D_2_2" unitRef="iso4217_USD">145000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
  <us-gaap:MarketableSecuritiesRealizedGainLoss contextRef="eol_PE730401--1410-Q0009_STD_92_20130930_0" decimals="INF" id="id_4670348_DAE93F34-720D-43E9-9828-5829AE57083D_3_1" unitRef="iso4217_USD">0</us-gaap:MarketableSecuritiesRealizedGainLoss>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE730401--1410-Q0009_STD_92_20130930_0" decimals="-3" id="id_4670348_DB100B7A-9F91-4F86-937E-D3A11E8F06D2_2_5" unitRef="iso4217_USD">-7062000</us-gaap:OperatingIncomeLoss>
  <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="eol_PE730401--1410-Q0009_STD_92_20130930_0" decimals="-3" id="id_4670348_DB100B7A-9F91-4F86-937E-D3A11E8F06D2_2_7" unitRef="iso4217_USD">-104000</us-gaap:InterestIncomeExpenseNonoperatingNet>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="eol_PE730401--1410-Q0009_STD_92_20130930_0" decimals="-3" id="id_4670348_DBE2D5B3-EBC6-464B-B7BC-30D3DADAFE8D_2_4" unitRef="iso4217_USD">-7233000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:NonoperatingIncomeExpense contextRef="eol_PE730401--1410-Q0009_STD_92_20130930_0" decimals="-3" id="id_4670348_DB100B7A-9F91-4F86-937E-D3A11E8F06D2_2_9" unitRef="iso4217_USD">-316000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="eol_PE730401--1410-Q0009_STD_92_20130930_0" decimals="-3" id="id_4670348_DB100B7A-9F91-4F86-937E-D3A11E8F06D2_2_8" unitRef="iso4217_USD">-212000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:Revenues contextRef="eol_PE730401--1410-Q0009_STD_92_20130930_0" decimals="-3" id="id_4670348_DB100B7A-9F91-4F86-937E-D3A11E8F06D2_2_0" unitRef="iso4217_USD">4566000</us-gaap:Revenues>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="eol_PE730401--1410-Q0009_STD_92_20130930_0" decimals="-3" id="id_4670348_DB100B7A-9F91-4F86-937E-D3A11E8F06D2_2_12" unitRef="iso4217_USD">-8335000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:NetIncomeLoss contextRef="eol_PE730401--1410-Q0009_STD_92_20130930_0" decimals="-3" id="id_4670348_DB100B7A-9F91-4F86-937E-D3A11E8F06D2_2_10" unitRef="iso4217_USD">-7378000</us-gaap:NetIncomeLoss>
  <us-gaap:OperatingExpenses contextRef="eol_PE730401--1410-Q0009_STD_92_20130930_0" decimals="-3" id="id_4670348_DB100B7A-9F91-4F86-937E-D3A11E8F06D2_2_4" unitRef="iso4217_USD">11628000</us-gaap:OperatingExpenses>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE730401--1410-Q0009_STD_92_20130930_0" decimals="-3" id="id_4670348_DB100B7A-9F91-4F86-937E-D3A11E8F06D2_2_2" unitRef="iso4217_USD">5348000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment contextRef="eol_PE730401--1410-Q0009_STD_92_20130930_0" decimals="-3" id="id_4670348_DB100B7A-9F91-4F86-937E-D3A11E8F06D2_2_11" unitRef="iso4217_USD">957000</us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment>
  <us-gaap:TemporaryEquityDividendsAdjustment contextRef="eol_PE730401--1410-Q0009_STD_92_20130930_0" decimals="-3" id="id_4670348_B37D91D9-3818-4BE8-B04C-25E44F2B6FC4_2_2" unitRef="iso4217_USD">883000</us-gaap:TemporaryEquityDividendsAdjustment>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE730401--1410-Q0009_STD_92_20130930_0" decimals="-3" id="id_4670348_DB100B7A-9F91-4F86-937E-D3A11E8F06D2_2_3" unitRef="iso4217_USD">6280000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE730401--1410-Q0009_STD_92_20130930_0" decimals="-3" id="id_4670348_6D77B0DA-1186-42D9-8241-0E457372E26C_2_2" unitRef="iso4217_USD">4320000</us-gaap:ShareBasedCompensation>
  <us-gaap:MarketableSecuritiesRealizedGainLossOtherThanTemporaryImpairmentsAmount contextRef="eol_PE730401--1410-Q0009_STD_92_20130930_0" decimals="INF" id="id_4670348_DAE93F34-720D-43E9-9828-5829AE57083D_3_2" unitRef="iso4217_USD">0</us-gaap:MarketableSecuritiesRealizedGainLossOtherThanTemporaryImpairmentsAmount>
  <bind:AccretionOfPreferredStockIssuanceCostsToRedemptionValue contextRef="eol_PE730401--1410-Q0009_STD_92_20130930_0" decimals="-3" id="id_4670348_B37D91D9-3818-4BE8-B04C-25E44F2B6FC4_2_1" unitRef="iso4217_USD">74000</bind:AccretionOfPreferredStockIssuanceCostsToRedemptionValue>
  <bind:ResearchAndDevelopmentCollaborationAgreementRevenue contextRef="eol_PE730401--1410-Q0009_STD_92_20130930_0" decimals="-3" id="id_4670348_D9FA225F-6D99-4C5D-B451-F03E65B46305_2_1" unitRef="iso4217_USD">4415000</bind:ResearchAndDevelopmentCollaborationAgreementRevenue>
  <us-gaap:DeferredRevenueRevenueRecognized contextRef="eol_PE730401--1410-Q0009_STD_92_20130930_0_1272072x1314996" decimals="-5" id="id_4670348_ED12A3E8-4383-4C29-8FDB-2DF3A8428EF4_1003_1" unitRef="iso4217_USD">1600000</us-gaap:DeferredRevenueRevenueRecognized>
  <us-gaap:DeferredRevenueRevenueRecognized contextRef="eol_PE730401--1410-Q0009_STD_92_20130930_0_1272072x1367107" decimals="-5" id="id_4670348_52F36303-2E76-4586-A3E2-681220880A58_1002_0" unitRef="iso4217_USD">1300000</us-gaap:DeferredRevenueRevenueRecognized>
  <us-gaap:DeferredRevenueRevenueRecognized contextRef="eol_PE730401--1410-Q0009_STD_92_20130930_0_1272072x1545620" decimals="-5" id="id_4670348_65524187-74EE-48E7-A63D-F61D3DA4864A_1002_0" unitRef="iso4217_USD">1400000</us-gaap:DeferredRevenueRevenueRecognized>
  <us-gaap:RevenueFromGrants contextRef="eol_PE730401--1410-Q0009_STD_92_20130930_0_1272072x1592869_1273333x1278099" decimals="-5" id="id_4670348_5F0954C3-DC3B-4A43-A300-67705006E574_1005_1" unitRef="iso4217_USD">200000</us-gaap:RevenueFromGrants>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE730401--1410-Q0009_STD_92_20130930_0_1274159x1269133" decimals="-3" id="id_4670348_6D77B0DA-1186-42D9-8241-0E457372E26C_1002_1" unitRef="iso4217_USD">3786000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE730401--1410-Q0009_STD_92_20130930_0_1274159x1269570" decimals="-3" id="id_4670348_6D77B0DA-1186-42D9-8241-0E457372E26C_2002_0" unitRef="iso4217_USD">534000</us-gaap:ShareBasedCompensation>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="eol_PE730401--1410-Q0009_STD_92_20140930_0" decimals="0" id="id_4670348_DB100B7A-9F91-4F86-937E-D3A11E8F06D2_1_16" unitRef="shares">16544402</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE730401--1410-Q0009_STD_92_20140930_0" decimals="2" id="id_4670348_DB100B7A-9F91-4F86-937E-D3A11E8F06D2_1_14" unitRef="iso4217_USD_per_shares">-0.44</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="eol_PE730401--1410-Q0009_STD_92_20140930_0" decimals="-3" id="id_4670348_DBE2D5B3-EBC6-464B-B7BC-30D3DADAFE8D_1_2" unitRef="iso4217_USD">-817000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
  <us-gaap:MarketableSecuritiesRealizedGainLoss contextRef="eol_PE730401--1410-Q0009_STD_92_20140930_0" decimals="INF" id="id_4670348_DAE93F34-720D-43E9-9828-5829AE57083D_2_1" unitRef="iso4217_USD">0</us-gaap:MarketableSecuritiesRealizedGainLoss>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE730401--1410-Q0009_STD_92_20140930_0" decimals="-3" id="id_4670348_DB100B7A-9F91-4F86-937E-D3A11E8F06D2_1_5" unitRef="iso4217_USD">-7593000</us-gaap:OperatingIncomeLoss>
  <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="eol_PE730401--1410-Q0009_STD_92_20140930_0" decimals="-3" id="id_4670348_DB100B7A-9F91-4F86-937E-D3A11E8F06D2_1_7" unitRef="iso4217_USD">-41000</us-gaap:InterestIncomeExpenseNonoperatingNet>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="eol_PE730401--1410-Q0009_STD_92_20140930_0" decimals="-3" id="id_4670348_DBE2D5B3-EBC6-464B-B7BC-30D3DADAFE8D_1_4" unitRef="iso4217_USD">-8091000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:NonoperatingIncomeExpense contextRef="eol_PE730401--1410-Q0009_STD_92_20140930_0" decimals="-3" id="id_4670348_DB100B7A-9F91-4F86-937E-D3A11E8F06D2_1_9" unitRef="iso4217_USD">316000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="eol_PE730401--1410-Q0009_STD_92_20140930_0" decimals="-3" id="id_4670348_DB100B7A-9F91-4F86-937E-D3A11E8F06D2_1_8" unitRef="iso4217_USD">357000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:Revenues contextRef="eol_PE730401--1410-Q0009_STD_92_20140930_0" decimals="-3" id="id_4670348_DB100B7A-9F91-4F86-937E-D3A11E8F06D2_1_0" unitRef="iso4217_USD">3365000</us-gaap:Revenues>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="eol_PE730401--1410-Q0009_STD_92_20140930_0" decimals="-3" id="id_4670348_DB100B7A-9F91-4F86-937E-D3A11E8F06D2_1_12" unitRef="iso4217_USD">-7277000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:NetIncomeLoss contextRef="eol_PE730401--1410-Q0009_STD_92_20140930_0" decimals="-3" id="id_4670348_DB100B7A-9F91-4F86-937E-D3A11E8F06D2_1_10" unitRef="iso4217_USD">-7277000</us-gaap:NetIncomeLoss>
  <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="eol_PE730401--1410-Q0009_STD_92_20140930_0" decimals="-3" id="id_4670348_DBE2D5B3-EBC6-464B-B7BC-30D3DADAFE8D_1_3" unitRef="iso4217_USD">3000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
  <us-gaap:OperatingExpenses contextRef="eol_PE730401--1410-Q0009_STD_92_20140930_0" decimals="-3" id="id_4670348_DB100B7A-9F91-4F86-937E-D3A11E8F06D2_1_4" unitRef="iso4217_USD">10958000</us-gaap:OperatingExpenses>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE730401--1410-Q0009_STD_92_20140930_0" decimals="-3" id="id_4670348_DB100B7A-9F91-4F86-937E-D3A11E8F06D2_1_2" unitRef="iso4217_USD">7131000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE730401--1410-Q0009_STD_92_20140930_0" decimals="-3" id="id_4670348_DB100B7A-9F91-4F86-937E-D3A11E8F06D2_1_3" unitRef="iso4217_USD">3827000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE730401--1410-Q0009_STD_92_20140930_0" decimals="-3" id="id_4670348_6D77B0DA-1186-42D9-8241-0E457372E26C_1_2" unitRef="iso4217_USD">587000</us-gaap:ShareBasedCompensation>
  <us-gaap:MarketableSecuritiesRealizedGainLossOtherThanTemporaryImpairmentsAmount contextRef="eol_PE730401--1410-Q0009_STD_92_20140930_0" decimals="INF" id="id_4670348_DAE93F34-720D-43E9-9828-5829AE57083D_2_2" unitRef="iso4217_USD">0</us-gaap:MarketableSecuritiesRealizedGainLossOtherThanTemporaryImpairmentsAmount>
  <bind:ResearchAndDevelopmentCollaborationAgreementRevenue contextRef="eol_PE730401--1410-Q0009_STD_92_20140930_0" decimals="-3" id="id_4670348_D9FA225F-6D99-4C5D-B451-F03E65B46305_1_1" unitRef="iso4217_USD">3365000</bind:ResearchAndDevelopmentCollaborationAgreementRevenue>
  <us-gaap:DeferredRevenueRevenueRecognized contextRef="eol_PE730401--1410-Q0009_STD_92_20140930_0_1272072x1314996" decimals="-5" id="id_4670348_ED12A3E8-4383-4C29-8FDB-2DF3A8428EF4_1002_1" unitRef="iso4217_USD">0</us-gaap:DeferredRevenueRevenueRecognized>
  <us-gaap:DeferredRevenueRevenueRecognized contextRef="eol_PE730401--1410-Q0009_STD_92_20140930_0_1272072x1324174" decimals="-5" id="id_4670348_8BD5C7E7-CB70-43EB-9E85-79AD257C419F_1001_0" unitRef="iso4217_USD">300000</us-gaap:DeferredRevenueRevenueRecognized>
  <us-gaap:DeferredRevenueRevenueRecognized contextRef="eol_PE730401--1410-Q0009_STD_92_20140930_0_1272072x1367107" decimals="-5" id="id_4670348_52F36303-2E76-4586-A3E2-681220880A58_1001_0" unitRef="iso4217_USD">2800000</us-gaap:DeferredRevenueRevenueRecognized>
  <us-gaap:DeferredRevenueRevenueRecognized contextRef="eol_PE730401--1410-Q0009_STD_92_20140930_0_1272072x1545620" decimals="-5" id="id_4670348_65524187-74EE-48E7-A63D-F61D3DA4864A_1001_0" unitRef="iso4217_USD">300000</us-gaap:DeferredRevenueRevenueRecognized>
  <us-gaap:RevenueFromGrants contextRef="eol_PE730401--1410-Q0009_STD_92_20140930_0_1272072x1592869_1273333x1278099" decimals="-5" id="id_4670348_5F0954C3-DC3B-4A43-A300-67705006E574_1002_1" unitRef="iso4217_USD">0</us-gaap:RevenueFromGrants>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE730401--1410-Q0009_STD_92_20140930_0_1274159x1269133" decimals="-3" id="id_4670348_6D77B0DA-1186-42D9-8241-0E457372E26C_1001_1" unitRef="iso4217_USD">378000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE730401--1410-Q0009_STD_92_20140930_0_1274159x1269570" decimals="-3" id="id_4670348_6D77B0DA-1186-42D9-8241-0E457372E26C_2001_0" unitRef="iso4217_USD">209000</us-gaap:ShareBasedCompensation>
  <bind:ReceivedUpfrontCashPayment contextRef="eol_PE730401--1410-Q0009_STD_97_20140630_0_1272072x1314996" decimals="-5" id="id_4670348_35927B44-47C3-4BE2-8DDA-A2D57A7BACE2_1001_0" unitRef="iso4217_USD">800000</bind:ReceivedUpfrontCashPayment>
  <bind:NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfChangeOnBasicAndDilutedEarningsPerShare contextRef="eol_PE730401--1410-Q0009_STD_97_20140630_0_1272072x1314996" decimals="2" id="id_4670348_ED12A3E8-4383-4C29-8FDB-2DF3A8428EF4_1001_0" unitRef="iso4217_USD_per_shares">0.05</bind:NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfChangeOnBasicAndDilutedEarningsPerShare>
  <context id="eol_PE730401--1410-Q0009_STD_97_20140630_0_1272072x1314996">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385228</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">bind:AmgenIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-03-26</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE730401--1410-Q0009_STD_92_20140930_0_1274159x1269570">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385228</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-07-01</startDate>
      <endDate>2014-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE730401--1410-Q0009_STD_92_20140930_0_1274159x1269133">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385228</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-07-01</startDate>
      <endDate>2014-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE730401--1410-Q0009_STD_92_20140930_0_1272072x1592869_1273333x1278099">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385228</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">bind:MinistryOfIndustryAndTradeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:RU</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-07-01</startDate>
      <endDate>2014-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE730401--1410-Q0009_STD_92_20140930_0_1272072x1545620">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385228</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">bind:PfizerIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-07-01</startDate>
      <endDate>2014-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE730401--1410-Q0009_STD_92_20140930_0_1272072x1367107">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385228</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">bind:AstraZenecaAbMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-07-01</startDate>
      <endDate>2014-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE730401--1410-Q0009_STD_92_20140930_0_1272072x1324174">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385228</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">bind:FHoffmannLaRocheLimitedMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-07-01</startDate>
      <endDate>2014-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE730401--1410-Q0009_STD_92_20140930_0_1272072x1314996">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385228</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">bind:AmgenIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-07-01</startDate>
      <endDate>2014-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE730401--1410-Q0009_STD_92_20140930_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385228</identifier>
    </entity>
    <period>
      <startDate>2014-07-01</startDate>
      <endDate>2014-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE730401--1410-Q0009_STD_92_20130930_0_1274159x1269570">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385228</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-07-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE730401--1410-Q0009_STD_92_20130930_0_1274159x1269133">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385228</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-07-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE730401--1410-Q0009_STD_92_20130930_0_1272072x1592869_1273333x1278099">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385228</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">bind:MinistryOfIndustryAndTradeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:RU</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-07-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE730401--1410-Q0009_STD_92_20130930_0_1272072x1545620">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385228</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">bind:PfizerIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-07-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE730401--1410-Q0009_STD_92_20130930_0_1272072x1367107">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385228</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">bind:AstraZenecaAbMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-07-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE730401--1410-Q0009_STD_92_20130930_0_1272072x1314996">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385228</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">bind:AmgenIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-07-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE730401--1410-Q0009_STD_92_20130930_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385228</identifier>
    </entity>
    <period>
      <startDate>2013-07-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE730401--1410-Q0009_STD_31_20131231_0_1272072x1314996">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385228</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">bind:AmgenIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-12-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE730401--1410-Q0009_STD_31_20130331_0_1272072x1545620">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385228</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">bind:PfizerIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-03-01</startDate>
      <endDate>2013-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE730401--1410-Q0009_STD_31_20141031_0_1271378x1273350">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385228</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-10-01</startDate>
      <endDate>2014-10-31</endDate>
    </period>
  </context>
  <context id="eol_PE730401--1410-Q0009_STD_31_20130131_0_1272072x1314996">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385228</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">bind:AmgenIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-01-31</endDate>
    </period>
  </context>
  <context id="eol_PE730401--1410-Q0009_STD_30_20130930_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385228</identifier>
    </entity>
    <period>
      <startDate>2013-09-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE730401--1410-Q0009_STD_30_20130630_0_1269523x1277596">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385228</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-06-01</startDate>
      <endDate>2013-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE730401--1410-Q0009_STD_30_20130430_0_1272072x1367107">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385228</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">bind:AstraZenecaAbMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-04-01</startDate>
      <endDate>2013-04-30</endDate>
    </period>
  </context>
  <context id="eol_PE730401--1410-Q0009_STD_273_20140930_0_1274159x1269570">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385228</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE730401--1410-Q0009_STD_273_20140930_0_1274159x1269133">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385228</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE730401--1410-Q0009_STD_273_20140930_0_1273383x1502643">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385228</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">bind:EmployeesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE730401--1410-Q0009_STD_273_20140930_0_1273383x1448784">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385228</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">bind:ConsultantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE730401--1410-Q0009_STD_273_20140930_0_1272072x1592869_1273333x1278099">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385228</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">bind:MinistryOfIndustryAndTradeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:RU</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE730401--1410-Q0009_STD_273_20140930_0_1272072x1545620">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385228</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">bind:PfizerIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE730401--1410-Q0009_STD_273_20140930_0_1272072x1367107">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385228</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">bind:AstraZenecaAbMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE730401--1410-Q0009_STD_273_20140930_0_1272072x1324174">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385228</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">bind:FHoffmannLaRocheLimitedMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE730401--1410-Q0009_STD_273_20140930_0_1272072x1314996">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385228</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">bind:AmgenIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE730401--1410-Q0009_STD_273_20140930_0_1269523x1277596">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385228</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE730401--1410-Q0009_STD_273_20140930_0_1268687x1275629">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385228</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE730401--1410-Q0009_STD_273_20140930_0_1268687x1273442">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385228</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE730401--1410-Q0009_STD_273_20140930_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385228</identifier>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE730401--1410-Q0009_STD_273_20130930_0_1276400x1554438">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385228</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bind:SeriesBRNPreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE730401--1410-Q0009_STD_273_20130930_0_1276400x1281158">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385228</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE730401--1410-Q0009_STD_273_20130930_0_1274159x1269570">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385228</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE730401--1410-Q0009_STD_273_20130930_0_1274159x1269133">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385228</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE730401--1410-Q0009_STD_273_20130930_0_1273383x1502643">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385228</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">bind:EmployeesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE730401--1410-Q0009_STD_273_20130930_0_1273383x1448784">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385228</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">bind:ConsultantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE730401--1410-Q0009_STD_273_20130930_0_1272072x1592869_1273333x1278099">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385228</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">bind:MinistryOfIndustryAndTradeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:RU</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE730401--1410-Q0009_STD_273_20130930_0_1272072x1545620">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385228</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">bind:PfizerIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE730401--1410-Q0009_STD_273_20130930_0_1272072x1367107">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385228</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">bind:AstraZenecaAbMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE730401--1410-Q0009_STD_273_20130930_0_1272072x1314996">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385228</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">bind:AmgenIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE730401--1410-Q0009_STD_273_20130930_0_1268687x1275629">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385228</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE730401--1410-Q0009_STD_273_20130930_0_1268687x1273442">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385228</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE730401--1410-Q0009_STD_273_20130930_0_1268687x1271210">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385228</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE730401--1410-Q0009_STD_273_20130930_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385228</identifier>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE730401--1410-Q0009_STD_1_20131023_0_1271382x1272538">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385228</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-10-23</startDate>
      <endDate>2013-10-23</endDate>
    </period>
  </context>
  <context id="eol_PE730401--1410-Q0009_STD_1_20131023_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385228</identifier>
    </entity>
    <period>
      <startDate>2013-10-23</startDate>
      <endDate>2013-10-23</endDate>
    </period>
  </context>
  <context id="eol_PE730401--1410-Q0009_STD_1_20130925_0_1271382x1272538">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385228</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-09-25</startDate>
      <endDate>2013-09-25</endDate>
    </period>
  </context>
  <context id="eol_PE730401--1410-Q0009_STD_1_20130925_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385228</identifier>
    </entity>
    <period>
      <startDate>2013-09-25</startDate>
      <endDate>2013-09-25</endDate>
    </period>
  </context>
  <context id="eol_PE730401--1410-Q0009_STD_1_20140325_0_1280964x1326831">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385228</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bind:TwoThousandThirteenIncentiveAwardPlanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-03-25</startDate>
      <endDate>2014-03-25</endDate>
    </period>
  </context>
  <context id="eol_PE730401--1410-Q0009_STD_0_20131231_0_1280806x1276695">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385228</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE730401--1410-Q0009_STD_0_20131231_0_1280806x1270387">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385228</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE730401--1410-Q0009_STD_0_20131231_0_1272289x1278641_1276335x1276695">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385228</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SecurityOwnedAndSoldNotYetPurchasedAtFairValueAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE730401--1410-Q0009_STD_0_20131231_0_1272289x1278641_1275669x1277587">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385228</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE730401--1410-Q0009_STD_0_20131231_0_1272289x1278641_1275669x1270387">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385228</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE730401--1410-Q0009_STD_0_20131231_0_1272289x1278641">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385228</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE730401--1410-Q0009_STD_0_20131231_0_1269038x1272304_1275669x1277587">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385228</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE730401--1410-Q0009_STD_0_20131231_0_1269038x1272304">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385228</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE730401--1410-Q0009_STD_0_20131231_0_1269038x1269048_1276335x1276695">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385228</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SecurityOwnedAndSoldNotYetPurchasedAtFairValueAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE730401--1410-Q0009_STD_0_20131231_0_1269038x1269048_1275669x1270387">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385228</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE730401--1410-Q0009_STD_0_20131231_0_1269038x1269048">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385228</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE730401--1410-Q0009_STD_0_20131231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385228</identifier>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE730401--1410-Q0009_STD_0_20121231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385228</identifier>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE730401--1410-Q0009_STD_0_20140930_0_1280964x1326831">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385228</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bind:TwoThousandThirteenIncentiveAwardPlanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-09-30</instant>
    </period>
  </context>
  <context id="eol_PE730401--1410-Q0009_STD_0_20140930_0_1280806x1276695">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385228</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-09-30</instant>
    </period>
  </context>
  <context id="eol_PE730401--1410-Q0009_STD_0_20140930_0_1280806x1270387">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385228</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-09-30</instant>
    </period>
  </context>
  <context id="eol_PE730401--1410-Q0009_STD_0_20140930_0_1272289x1278641_1276335x1276695">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385228</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SecurityOwnedAndSoldNotYetPurchasedAtFairValueAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-09-30</instant>
    </period>
  </context>
  <context id="eol_PE730401--1410-Q0009_STD_0_20140930_0_1272289x1278641_1275669x1277587">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385228</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-09-30</instant>
    </period>
  </context>
  <context id="eol_PE730401--1410-Q0009_STD_0_20140930_0_1272289x1278641_1275669x1270387">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385228</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-09-30</instant>
    </period>
  </context>
  <context id="eol_PE730401--1410-Q0009_STD_0_20140930_0_1272289x1278641">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385228</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-09-30</instant>
    </period>
  </context>
  <context id="eol_PE730401--1410-Q0009_STD_0_20140930_0_1269523x1275948_1280806x1270387">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385228</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-09-30</instant>
    </period>
  </context>
  <context id="eol_PE730401--1410-Q0009_STD_0_20140930_0_1269038x1272304_1275669x1277587">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385228</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-09-30</instant>
    </period>
  </context>
  <context id="eol_PE730401--1410-Q0009_STD_0_20140930_0_1269038x1272304">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385228</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-09-30</instant>
    </period>
  </context>
  <context id="eol_PE730401--1410-Q0009_STD_0_20140930_0_1269038x1269048_1276335x1276695">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385228</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SecurityOwnedAndSoldNotYetPurchasedAtFairValueAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-09-30</instant>
    </period>
  </context>
  <context id="eol_PE730401--1410-Q0009_STD_0_20140930_0_1269038x1269048_1275669x1270387">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385228</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-09-30</instant>
    </period>
  </context>
  <context id="eol_PE730401--1410-Q0009_STD_0_20140930_0_1269038x1269048">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385228</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-09-30</instant>
    </period>
  </context>
  <context id="eol_PE730401--1410-Q0009_STD_0_20140930_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385228</identifier>
    </entity>
    <period>
      <instant>2014-09-30</instant>
    </period>
  </context>
  <context id="eol_PE730401--1410-Q0009_STD_0_20131023_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385228</identifier>
    </entity>
    <period>
      <instant>2013-10-23</instant>
    </period>
  </context>
  <context id="eol_PE730401--1410-Q0009_STD_0_20130930_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385228</identifier>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE730401--1410-Q0009_STD_0_20130925_0_1271382x1272538">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385228</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2013-09-25</instant>
    </period>
  </context>
  <context id="eol_PE730401--1410-Q0009_STD_0_20130630_0_1269523x1277596">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385228</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2013-06-30</instant>
    </period>
  </context>
  <context id="eol_PE730401--1410-Q0009_STD_0_20130430_0_1272072x1367107">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385228</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">bind:AstraZenecaAbMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2013-04-30</instant>
    </period>
  </context>
  <context id="eol_PE730401--1410-Q0009_STD_0_20130331_0_1272072x1545620">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385228</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">bind:PfizerIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2013-03-31</instant>
    </period>
  </context>
  <context id="eol_PE730401--1410-Q0009_STD_0_20141031_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385228</identifier>
    </entity>
    <period>
      <instant>2014-10-31</instant>
    </period>
  </context>
  <unit id="shares">
    <measure>shares</measure>
  </unit>
  <unit id="iso4217_USD">
    <measure>iso4217:USD</measure>
  </unit>
  <unit id="iso4217_USD_per_shares">
    <divide>
      <unitNumerator>
        <measure>iso4217:USD</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>shares</measure>
      </unitDenominator>
    </divide>
  </unit>
  <unit id="pure">
    <measure>pure</measure>
  </unit>
  <unit id="iso4217_RUB">
    <measure>iso4217:RUB</measure>
  </unit>
  <unit id="Installment">
    <measure>bind:Installment</measure>
  </unit>
  <unit id="Executives">
    <measure>bind:Executives</measure>
  </unit>
  <unit id="Option">
    <measure>bind:Option</measure>
  </unit>

</xbrl>